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Abstract

MICRORNA FUNCTIONS IN UV-INDUCED
CUTANEOUS SQUAMOUS CELL CARCINOMA
Tran Nguyen, B.Pharm.

Advisory Professor: Kenneth Y. Tsai, M.D., Ph.D.

Cutaneous squamous cell carcinoma (cuSCC) is the second most common skin cancer,
for which long term UV exposure and chronic wounding are the dominant risk factors. Despite
these clinically established connections, little is understood about the early molecular response
of human skin to UV exposure and its connection to acute wounding and cuSCC. Thus, our goal
is to find common and specific signatures driven by UV-exposure and wounding as a means of
developing new approaches for treating and preventing cuSCC.
Here, we perform integrated analyses of RNA-seq and miR-seq on 3 datasets: (1) UVunexposed and acute UV-exposed human skin, (2) public dataset on acute wound healing and
(3) our previously published dataset on normal skin and cuSCC from humans. We find that
biological signatures and processes regulated by acute UV exposure and wounding has profound
similarity.
Through RNA-seq and miR-seq on matched normal skin and cuSCC tumors from
humans and a UV-driven mouse model, as well as acute UV-exposed human skin, we were able
to identify a group of miRs that change both in cuSCC development and following UV
v

exposure. We previously reported that miR-21-5p and miR-31-5p overexpression correlates
with the development of UV-induced cuSCC in human. This is also true for our analysis where
we find that these miRs as well as miR-21-3p are upregulated by more than 6-fold in cuSCC
(compared to normal skin) and more than 2.5-fold in UV-exposed skin (compared to unexposed
skin). In addition, we identify that miR-340-5p and let-7i-5p are novel candidates that have not
been previously linked to either cuSCC development or the UV response of human skin.
This suggests that these changes in miRNA-RNA are important early events that
regulated by both UV-exposure and wounding which eventually can promote cuSCC initiation.
Thus, our findings suggest that UV-exposed skin, wound and cuSCC share various common
signatures, which can be potentially validated as chemopreventive targets for cuSCC.
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Chapter 1: Introduction
1.1 Cutaneous Squamous Cell Carcinoma: Background and Motivation
Cutaneous squamous cell carcinoma is the second most common skin cancer, surpassed
only by basal cell carcinoma (1, 2). Annually, an estimated of over 250,000 new cases of cuSCC
are diagnosed in the United States (3). In 2012, 3900 to 8700 people in the United Stated died
from cuSCC. Although the exact incidence of cuSCC is unknown since it has not been included
in national cancer registries, this incidence has been recorded to steadily rise during the last four
decades in both men and women (Figure 1) (3). Risk factors for cutaneous squamous cell
carcinoma include chronic sun exposure, older age, and impaired immune surveillance with sun
exposure being the main etiological factor (4). It is well-established that actinic keratosis (AKs)
are pre-neoplastic lesions that can progress to cuSCC. The rate of progression occurs at a
statistically low of 10% annually (5).

1

Figure 1
Increase in age-adjusted incidence of cutaneous squamous cell carcinoma in sun zone 2 by
gender with average, plateau, and constant increase assumption incidence estimates ( X ). This
figure is reproduced based on previously published figure (3)

2

From the clinician’s perspective, cuSCC is highly curable and more than 95% of cuSCC
patients were cured with surgical excision (4). Nevertheless, there is a subset of aggressive
cuSCC tumors recur or metastasize, resulting in a 2.1% risk of disease specific death overall (6,
7). In immunosuppressed patients, cuSCC displays more rapid growth, has 13% risk of
recurrence, and 5-8% risk of metastasis (8). Once a cuSCC has recurred, it has a much worse
prognosis, with risk of metastasize to lymph nodes and distant organs cited as high as 45% (9).
Given its steep rise in incidence, limited therapeutic options for advanced or metastatic
disease and potential for poor outcomes, cSCC is emerging as a public health problem. Thus,
understanding the genomic signatures of cuSCC can help identify potential predictive
biomarkers that can dictate prevention and upfront treatment approaches.

1.2 High-risk cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (SCC) includes many subtypes with widely varying
clinical behaviors, ranging from easy-to-manage indolent to aggressive tumors with significant
metastatic potential.
It is well documented that immunosuppressed patients due to solid organ transplantation
are at greater risk of developing cSCC, with an estimated 65-fold increase compared to the
general population (10). The cuSCC to basal cell carcinoma ratio is reversed in the
immunosuppressed population. While cuSCCs make up 20% and basal cell carcinomas make up
80% of NMSCs in immunocompetent patients (10, 11). These cancers are more aggressive, with
an increased risk of metastases (12). Recurrence and mortality rates are also higher in patients
who are immunosuppressed (5%) than those who are immunocompetent (1%) (13, 14).
3

In addition to immunosuppressed patients, patients who suffer from chronic skin
injuries, such as wounds, or burns, are at increased risk of developing aggressive cSCC (13).
Included in this subgroup are patients with a genetic predisposition to skin injury, including
epidermolysis bullosa, xeroderma pigmentosum, and congenital dyskeratosis (13, 15, 16).

1.3 Genomic background of cuSCC development
Like other cancers, the development of cuSCC is likely a multi-step process, involving
sequential acquisition of genetic changes. The genomic profile of AKs, the precursors of
cuSCC, significantly overlaps that of cuSCC (17). Previously reported, cuSCC tumors features
very high background mutation rate with a significant enrichment in UV signatures (Figure 2)
(17, 18). UVB exposure is known to cause C>T transitions often following a pyrimidine base.
The mutation spectrum of cuSCC is quite similar to that of head and neck cutaneous squamous
cell carcinoma (HNSCC) except for the UV signature. In cuSCC, high frequencies of
inactivating mutation were found to occur in major tumor suppressors TP53, CDKN2A,
NOTCH1 and NOTCH2 (17-19).
1.4 UV spectrum of solar radiation (UVR)
Ultraviolet (UV) rays are a form of invisible energy given off by the sun. Based on
wavelength solar UV radiation (UVR) is divided into three ategories, UVA (320-400nm), UVB
(280-320nm) and UVC (100-280nm). Minute amount of UVC reaches the earth surface by
penetrating the ozone layer of atmosphere and for this reason UVC is not physiologically
relevant for studies of human skin cancer. On the other hand, UVA rays account for the majority
4

(95%) of the UV radiation reaching the earth's surface; terrestrial radiation from the midday sun
comprises about 95% UVA and 5% UVB [17]. UVA is mainly responsible in the aging of the
cells and some DNA damage. On the other hand, UVB rays cause direct DNA damage and
responsible for sunburns. UVA rays can penetrate deeply into the skin and mainly cause dermal
compartment damage while UVB damage is mainly in the epidermal compartment. UV
radiation can cause an increase in collagen breakdown and abnormal deposition of elastin [18,
19]. This process and it’s pathological manifestation is referred to as solar elastosis. In addition,
UV radiation can cause an increase in free radicals resulting in damage of cellular functions and
DNA damage. Moreover, UV radiation can suppress the immune system by inducing release of
certain cytokines, inhibiting antigen presentation, and enhancing leukocytes apoptosis [20].

5

Figure 2
Key mutations in cSCC. Total number of mutations per patient is shown on the top.
Inactivating mutations include nonsense, frameshift, and splice site events. This figure is
reproduced based on previously published figure (17).
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At the chromosomal level, several studies have shown that cuSCC can display complex
karyotypes with large numbers of allelic imbalances (20, 21) .Moreover, widespread gains and
losses of chromosomal fragments have been reported to be already present in AKs (22).
It has been challenging to identify drivers of progression to cuSCC from normal skin as
multiple studies show little overlap in differentially expressed (DE) genes in their genome-wide
transcriptional profiles. Majority of the studies have employed cuSCC cell lines or small cohorts
of unmatched normal skin, AKs and cuSCC tissues on several platforms known to have
potentially high annotation error rates (23-26). Using normal skin, AKs and cuSCC tissues
derived from patients received immunosuppressive drugs, Hameetman at el. suggested that the
NFκB1 and TNF pathways activated as early as AKs stage while RAS and MYC oncogenic
pathways appear to be specifically activated in cuSCC (23). Using cross-species approach on
sporadic cuSCC in human and UV-induced cuSCC in mouse, our lab has identified several key
early transcriptional drivers of cuSCC include E2F, ELK1 and NFY (17). These early findings
serve as foundation for further transcriptomics studies of UV-induced cuSCC.
1.5 UV-induced hairless mouse model
In cuSCC research, there are currently two types of mouse model being widely used.
The differences lie on how the tumors were induced. The first one is the two-stage chemically
induced skin carcinogenesis model (27). In brief, a subcarcinogenic dose of carcinogen 7,12dimethylbenz[a]-anthracene (DMBA) (Figure 3) was applied onto the mouse skin, followed by
repeated application of tumor promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA).
This model allows the initiation and promotion stages can be distinctly separated both
7

operationally and mechanistically. In lesions initiated by this method, mutations in Hras1 (A →
T (182) transversion in codon 61) Kras, and Trp53 were observed (28-31). Although the
chemically-induced mouse model proved to be extremely useful and faithful in creating
papillomas and cuSCCs, the need for a mouse model that better captured the genomic features
of human UV-induced cuSCC emerged.

Figure 3
Two-stage model of skin carcinogenesis in mice
8

This figure is reproduced based on previously published figure (27).
During initiation, topical application of a sub-carcinogenic dose of a mutating agent
induces mutations in target genes in keratinocyte stem cells. Repeated topical application of a
promoting agent begins two weeks after initiation and continues for the duration of the study.
Papillomas begin to arise after approximately 6–12 weeks of promotion and a fraction begin to
convert to SCC after approximately 20 weeks. Representative H&E stained sections of normal
skin, hyperplastic skin, a papilloma, and a SCC are presented. All mice were handled in
accordance with institutional and national regulations. This figure is reproduced based on
previously published figure (27).
The second cuSCC mouse model is UV-induced SKH1 hairless mouse model. Tumors
induced in these mice resemble both at the morphologic and molecular levels, UV-induced skin
malignancies in human. Although there are various strains of hairless mice, outbred albino
SKH1 is the strain most extensively used for Wound healing, acute photobiologic responses,
and skin carcinogenesis. We chose this model to avoid chronic irritation as a confounding
variable in our studies that is due to depilation of mice. In addition, with this model we can
eliminate the effects of hair cycle on skin carcinogenesis.
Murine Hr gene locates at the 70Mb on mouse chromosome 14. In mice, Hr gene
encodes a ~130kDa protein (32). The HR protein is a transcriptional co-repressor, binding to
thyroid hormone, vitamin D, and retinoic acid receptor-related orphan receptors but not to
retinoic acid or glucocorticoid receptors (33). Embryonically, Hr is expressed in various tissues
and highly expressed in both hair follicle and interfollicular keratinocytes of epidermis by birth.
The mutant allele that is carried by SKH1 mice is autosomal recessive, hr, which has an
9

aberrant splicing due to stable integration of a retrovirus into the 6th intron of the gene. In
human, two autosomal recessive diseases are associated with Hr mutations. Various studies
have shown that for normal hair growth Hr is necessary and sufficient (34). Hair growth in
hairless mice is normal during the first hair cycle; however, mice rapidly lose hair starting
cephalically and proceeding caudally(34). During consecutive hair cycles, follicles develop
abnormally with characteristic histological findings of utriculus, deep dermal cysts, and
sebaceous gland hyperplasia (34).
Each mouse can produce multiple skin tumors, independent of one another, and this
feature can be used to discern the rate of development and individual aggressiveness of each
tumor. Tumor progression starts from epithelial hyperplasia which then progresses to papilloma
and eventually into carcinoma. From this progression sequence, we can identify markers for
tumor initiation, promotion and progression. Hairless mice have been shown to be sensitive to
development of UV-induced carcinoma that have similar pattern of mutations as human cuSCC.
Of important note, haired mice are less susceptible to UVR immunosuppressive effects than
nude mice. In the SKH-1 Hairless mouse model of UV-induced cuSCC, p53, RAS, and
CDKN2A are similarly affected as seen in human cuSCC [7-16].

10

Figure 4
Cross-species transcription factor motif analysis reveals major drivers of cuSCC
development.
(a) Global view of transcription factors with target genes enriched across the entire
NS/CHR to AK/PAP to cuSCC progression sequence. Directionality reflects the significant
11

upregulation (above the line) or downregulation (below the line) of predicted targets of the
listed transcription factors. Some factors have targets that are enriched in opposite directions
across distinct transitions. The transcription factors highlighted in red were identified in both
TRANSFAC and LME-based analyses. (b) Network analysis demonstrates that core
transcriptional drivers are highly interconnected in both human (left) and mouse (right). The
bolded lines delineate connections that are significant by Fisher exact test (P<10−4). (c) The
LME model of mRNA expression changes across cuSCC development in both species
demonstrates that the vast majority of significant gene expression changes occur in the early
transition from NS/CHR to AK/PAP. This figure is reproduced based on previously published
figure (17).

1.6

MicroRNA landscape in UV-induced cutaneous squamous cell carcinoma

1.6.1. MicroRNA biogenesis
MicroRNAs (miRNAs) comprise a class of non-coding regulatory RNAs of 20-25
nucleotides that regulate transcription of numerous genes mainly by binding to complementary
sequences on the 3′ untranslated regions (3′-UTRs) of the target genes. miRNA biogenesis is a
complex but fairly well understood process. The biogenesis of miRNAs initiated in the nucleus
and complete in the cytoplasm. In the nucleus, primary transcripts (pri-miRNA) are transcribed
by RNA polymerase II and cleaved into precursor miRNAs (pre-miRNAs) by the ribonucleases
Drosha and DGCR8. Then, pre-miRNAs are exported into the cytoplasm for additional cleavage
by a ribonuclease called Dicer. The mature miRNA is a part of the RNA-induced silencing
12

complex (RISC) where they bind to a specific seed sequence on the 3’UTR of target genes. If
the 3′-UTR site is fully complementary to the miRNA, the mRNA is targeted for
degradation (35). Since the first discovery of miRNAs in the early 1990s, a large amount of
studies have focused on uncovering the biological relevance of these small RNAs in skin cancer
initiation, development and metastasis.

Figure 5
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Nuclear events in the miRNA biogenesis pathway. This figure is reproduced based on
previously published figure. (36)
1.6.2. MicroRNAs in skin cancer
Current data established the crucial roles of some miRNAs in controlling the transition
of skin stem cells along certain differentiation lineages (37-39). Here, miRNAs are involved in
controlling the expression of key regulators of stem cell activity in normal healthy skin and hair
follicles. miR-203 regulates the p63-dependent proliferative potential of epithelial precursor
cells during keratinocyte differentiation by repressing DeltaNp63 (40). miR-125b control stem
cell proliferation, fate commitment and differentiation (38). miR-31 ensures proper hair follicle
growth by targeting a number of growth regulatory molecules and cytoskeletal components of
the WNT and FGF signaling pathways (41).
A large body of literature shows that miRNAs are abnormally expressed in tumors.
While tumors often overexpress oncogenic miRNAs (e.g., miR-155, miR-21 and miR-17∼92
miR family) that promote cancer cells tumorigenesis, certain tumor suppressor miRNAs are
regularly downregulated in cancers (e.g., let-7, miR-16) (42, 43). Due to this, miRNAs might
represent important diagnostic tools in cancer as well as possible targets for anticancer
treatments. Much research in the area has found that in many cases, a specific microRNA can
be oncogenic in one cancer and tumor suppressor in another cancer. For example, antiinflammatory miR-223 promotes gastric cancer metastasis by targeting EPB41L3 while
suppresses proliferation and migration of nasopharyngeal carcinoma cells through MAFB (44,
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45). Therefore, the need to characterize miRNA-mRNA regulatory networks in specific
cancer settings is crucial.
Like in other cancers, miRNAs have been associated with the initiation and progression
of squamous cell carcinoma of the skin by multiple studies. miR-21 was found to be the only
miRNA consistently overexpressed in 540 clinical samples in of cancer patients. The
importance of miR-21 in tumor development has been documented in multiple studies including
melanoma (46). A significant upregulation of miR-31, a proto-oncogene like miR-31 was
observed. miR-31 can have tumor-suppressive and oncogenic roles in different tumor types. In
colorectal cancer, miR-31 expression is associated with the progression of the disease (47).
An adequate amount of evidence points to the conclusion that miRNAs play an
important role in biology of cuSCC. Specific miRNAs might be used as diagnostic and
prognostic markers but also to develop targeted or personalized anti-cuSCC treatments.
Understanding in detail the function of miRNAs in cuSCC will open new opportunities for
modern medicine and clinical application.
1.6.3. MicroRNA target identification
Computational prediction tools continue to be the first routine step in identifying
miRNA targets. These tools are usually based on the phylogenetically conserved
complementarity of miRNAs to their potential target genes (48). However, seed pairing may not
be an fully accurate predictor (49). Therefore, the interaction between microRNA and its target
genes must still be validated to reveal the functions of microRNA. The validation method
involves well-established techniques, such as qRT-PCR, luciferase reporter assay and western
15

blot (50). Western blot and qRT-PCR measure the expressions level of protein and the mRNA
level, respectively. Reporter assays are dependable methods for elucidating the direct interaction
between microRNA and its target gene (51).

There are currently two types of miRNA targets prediction tools: databases with
experimental data and computational algorithms. The most highly cited experimental public
database is miRTarBase (52) and miRWalk with miRTarBase being more frequently updated.
These experimental databases collect data using various methods including: PCR, Western blot,
proteomics, microarray, etc. (Table 2).

Database

Number of entry

Version/year

Reference

TarBase

miRNA–gene

TarBase (2006)

http://diana.imis.athenainnovation.

(53) (54)

interactions:65 814

Tarbase 5 (2008)

gr/DianaTools/index.

Species :24

Tarbase

Paper curate: 10,000

(2012)

name

6.0 php?r=tarbase/index

TarBase (2014)
miRecords

miRNA-gene

miRecords

(55)

interaction: 2705

(2008)

miRNA: 664

last updated

gene:1907

from

9 April 2013

16

http://mirecords.biolead.org/

animal
Curated from low
through

put

experiment:2028
miRGator

Mature miRNA: 1856

miRGator (2008)

http://mirgator.kobic.re.kr/

(56)

Validated target:4745

miRGator (2011)

http://genome.ewha.ac.kr/miRGator/

Predicted target :6 218 miRGator (2013)
792
miRWalk

858,750,070

miRwalk

(57)

interactions

(2010)

between

1.0 http://www.umm.uni-heidelberg.
de/apps/zmf/mirwalk/

11,748 miRWalks2.0

miRNAs and

(2014)

308,700 genes
miRTarBase Species: 18

miRTarBase 1.0 http://mirtarbase.mbc.nctu.edu.

(52)

Target genes: 22,563

(2010)

miRNAs: 3786

miRTarBase 4.0

miRNA–target

(2014)

interactions:

miRTarBase

366,181
4966

tw/index.php

Articles: 5.0(2015)
miRTarBase
6.0(2016)

17

miRTarBase
7.0(2017)
miRSel (58)

Human (2112 pairs)

miRSel (2010)

Mouse (895 pairs)

http://services.bio.ifi.lmu.de/
mirsel/

Rat (231pairs)
Other organism: (452
pairs)
starBase

miRNA-circRNA:

StarBase (2011)

(59)

9000

Starbase (2014)

http://starbase.sysu.edu.cn

miRNA-pseudogene:
16 000
protein–RNA:

285

000
PMTED

miRNA:1897

(60)

Target: 5449

PMTED (2013)

http://pmted.agrinome.org/

Species:12
Experiment:311
Assay:3492
ComiRNet

5 million MTIs

(61)

miRNA: 934

ComiRNet(2015) http://www.comirnet.di.uniba.it

mRNA:30,835
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biclusterhierarchies:15
MtiBase

Gene: 15,546

MtiBase(2015)

(62)

miRNA: 4420

http://mtibase.sysu.edu.cn

4 400 000 CDS 470 000 5′UTR
miRNA target sites
SNP

influence

290,000 CDS
and

28,000

5′UTR

miRNA
target sites

Table 1.
miRNA target databases based on experimental data

Current prediction algorithms based on structural characteristics can be categorized into
three groups: ab initio, machine learning and hybrid approaches (63, 64). The ab initio
algorithms are based on computational models that do not use the experimental data directly but
instead, make the prediction based on the structural features extracted from data. This approach
usually leads to high false positive. Machine learning approaches, on the other hand, use
computational algorithms that rely directly on experimental data for training. However, negative
interactions with experimental support are usually discarded. The limitations of ab initio and
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machine learning algorithms, have led to the development of hybrid algorithms with features
from both methods incorporated. A summarizing table of algorithms can be found below.

Database name

Class

Reference

miRanda (65)

ab initio

http://www.microrna.org

weighted dynamic programming algorithm
TargetScan (66) ab initio
(67) (68)

ranked

http://www.targetscan.org/
base

on

hierarchy

(6mer

offset < 6mer < 7mer-A1 < 7merm8 < 8mer)
PicTar (69)

ab initio

http://pictar.mdc-berlin.de/

targets are ranked based on a score derived
using a hidden Markov model
RNA22 (70)

RNAhybrid (71)

PITA (72)

ab initio

http://cbcsrv.watson.ibm.co

pattern discovery using Markov chain

m/rna22.html

ab initio

http://bibiserv.techfak.uni-

computes the minimum free energy

bielefeld.de/rnahybrid/

ab initio

http://genie.weizmann.ac.il
/pubs/mir07/

EiMMo (73)

ab initio

(http://www.mirz.unibas.ch

Bayesian method

/ElMMo2/
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DIANA (74)

ab initio

http://diana.cslab.ece.ntua.
gr/microT/

miTarget (75)

SVM

http://cbit.snu.ac.kr/xmiTar
get/introduction.html

Ensemble

SVM

a post-processing step for

Algorithm

miRanda

(76)
NBmiRTar (77)

Naïve Bayes classifier

post-processing

step

to

miRanda
MirTarget2 (78)

SVM

http://mirdb.org

MiRTif

SVM

http://mirtif.bii.a-

Combines sets from

star.edu.sg/

miRanda, PicTar and TargetScan
MTar (79)

SVM

http://www.rgcb.res.in/dow
nloads/Mtar.rar

TargetSpy (80)

automatic feature selection

http://www.targetspy.org/

HITS-CLIP
mirSVR (65)

miRanda followed by a support vector http://www.microrna.org
regression

mirror (81)

unified platform generated from several ab http://www.proto.cs.huji.ac
initio predictors

.il/mirror/search.php
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miREE (82)

hybrid algorithm

http://didatticaonline.polito.it/eda/miREE/

Table 2
miRNA target prediction tools based on mathematical models

Identifying the target of a specific miRNA is crucial in understanding the role of the
miRNA in biological processes. MiRNA, however, can target thousands of genes (66, 83). Over
the better part of the last two decades, experimental and computational prediction tools have
been developed to facilitate microRNA research (63, 64). Although each has predictive power,
they all have limitations based on the scoring and integration of features into the
tool. Understanding the principle of these prediction methodologies will aid in the
appropriate tools selection and tool output interpretation.

1.7 Pathway analysis for genome-wide association study data: An overview
High-throughput experiments (e.g. microarray, next-generation sequencing, or
proteomics) have transformed biomedical research by enabling comprehensive monitoring of a
biological system. Analysis NGS data typically yields a useful list of differentially expressed
genes or proteins. However, this gene list of thousands of rows often fails to provide insights
into the underlying biology of the condition being studied. To reduce the complexity of the data,
one approach has been to group long lists of individual genes into smaller sets of related genes
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or proteins. Researchers have developed a large number of pathway databases (e.g. KEGG (84),
Ingenuity, MSigDB, Wikipathways) to help with this task. The pathway databases describe
biological processes, components, or structures in which individual genes and proteins are
known to be involved in, as well as how and where gene products interact with each other
(Table 1) (85-87).

PDB Name

Pathway focus

URL

Y.O.R.

Formats

EcoCyc

M,S

biocyc.org

1995

SBML,
BioPAX

KEGG

M,S,D

kegg.jp

1996

BioPAX

RegulonDB

GR

regulondb.ccg.unam.mx

1997

BioPAX

MetaCyc

M

metacyc.org

1999

SBML,
BioPAX

STRINGDB

PPI

string-db.org

2000

PSI-MI

PANTHER

S,D,PS

pantherdb.org

2004

SBML,
SBGN,
BioPAX

Gene Ontology

PPI,M,S

geneontology.org

2000

REACTOME

M,S,D

reactome.org

2005

SBML,
SBGN,

23

BioPAX,
PSI-MI
MSigDb

M,S,GR

broadinstitute.org/gsea/

2005

msigdb
Ingenuity

PPI,PCI,M,S,GR,

ingenuity.com

2005

Knowledge Base* D
NCI PID

S,D

pid.nci.nih.gov

2006

BioPAX

WikiPathways

M,S,D

wikipathways.org

2008

BioPAX

smpdb.ca

2009

SBML,

Small

Molecule M,S

Pathway DB
ConsensusPathD

BioPAX
PPI,PCI,M,S,GR

consensuspathdb.org

2009

B
Pathway

BioPAX,
PSI-MI

PPI,PCI,M,S

pathwaycommons.org

2010

BioPAX

Commons

Table 3
Pathway databases. A brief example of the diversity of available PDBs found online. The
second column shows the kind of biological focus pursued by each database: (PPI, proteinprotein intereactions; PCI, protein-compound interactions; M, metabolic; S, signaling; GR, gene
regulation; D, diagrams; PS, protein sequence). The last column addresses the standard pathway
languages adopted to provide data. Additionally, in the third column the links to web sites are
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supplied. YOR, Year of release. *Commercial database. This table is reproduced based on
previously published data.
1.7.1

Over-Representation Analysis (ORA): First Class pathway analysis

ORA approach has become a routine task in functional genomics studies. The basic
hypothesis in ORA is that relevant pathways can be detected if the proportion of differential
expressed genes, within a given pathway, exceeds the proportion of genes that could be
randomly expected. The confidence level of overlapping is calculated using statistical
methods such as hypergeometric, chi-square, or binomial distribution. Popular tools
implementing this idea include DAVID (88), BINGO (89), and GeneMania (90).
Despite the availability of a large number of tools and their widespread usage, traditional
ORA have a number of limitations. First, the different statistics used by ORA are independent of
the measured changes (85). This means that these tests consider the number of genes alone and
ignore any values associated with them such as fold-changes or significance of changes. By
discarding this data, ORA treat each gene with equal weight or importance and assume that each
gene is independent of the other genes. Assuming independence between genes amounts to
“competitive null hypothesis” testing, which ignores the correlation structure between genes
(85). For example, a gene may act as the regulator of a number of genes inside the same
pathway, and the perturbation of this gene may have a larger impact on the pathway than the
perturbation of its target genes do. Consequently, the estimated significance of a pathway may
be biased or incorrect. Second, ORA uses arbitrary user cut-off threshold, that leaves out
potentially important information and generates result variability (91). To date, there is no rule
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of thumb for establishing a cut-off threshold. Finally, ORA assume that each pathway is
independent of other pathways, which is contrary to the acknowledgement of interaction
between pathways (86, 92). To find a more precise model of biological systems, pathway
analysis has to evolve to address the discussed limitation. This led to the second class of
pathway analysis method.
1.6.2 The Second Generation: Functional Class Scoring (FCS)

These methods work under the main hypothesis that although large changes in gene
expression have significant effects on a pathway, weaker but coordinated changes in the genes
that assemble the pathway have an impact on the overall pathway state. In this way Functional
Class Scoring (FCS) methods use all the available measurements in NGS data to evaluate their
enrichment scores, but still using pathways as gene sets to perform their computations. FCS
methods use a three-step framework that consists of gene-level statistics, pathway-level
statistics and assessment of the statistical significance of the pathway-level statistic.

An important improvement of FCS methods over ORA is that they are built to use all
available measurements from NGS data. They do not need an arbitrary cut-off threshold of
differentially expressed genes. Also, they can detect differences between pathways that are
barely passing the differentially expressed thresholds and the ones that are passing them with
significance levels. They can also detect coordinated associations between genes and their
belonging pathways.
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One of the first and most popular methods deploying the FCS approach is the Gene Set
Enrichment Analysis (93), which was developed by researchers from the Broad Institute for
gene expression analysis from microarray data. In brief, GSEA uses a list of ranked genes in
accordance to their differential gene expression between two biological states (93). Then,
evaluates their distribution on pre-defined gene sets, (i.e., gene sets from the MSigDB) thus
computing an enrichment score (ES) for each set of genes (through a Kolmogorov-Smirnov
pathway-level statistic) to determine whether it shows statistically significant, concordant
differences between two biological states (93).

Another popular FCS tool is Ingenuity Pathway Analysis (IPA) canonical pathway
owned by QIAGEN (Hilden, Germany). IPA charges a user fee and maintains their own
knowledge base to compare gene expression data to. They, however, incorporate causal
analytics tools in their ‘Upstream Regulator Analysis', ‘Mechanistic Networks', ‘Causal
Network Analysis' and ‘Downstream Effects Analysis'. In particular, IPA uses two
measurements that address two independent aspects of the inference problem: an enrichment
score (Fisher’s exact test) that measures the overlap significance, and a Z-score assessing the
match of observed and take direction of change into account. Here, Z-score serves as both a
significance measure and a predictor for the activation state of the regulator (94). This is a
significant advancement over traditional FCS tools which just look for statistical enrichment in
overlap to sets of genes.

Although an improvement over ORA, FCS has several setbacks. First, they do not take
the relationships between pathways components or pathway network configuration into account
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(95). This issue has been partially addressed by Ingenuity causal network analysis (94). Second,
similar to ORA, FCS analyzes each pathway independently from each other, not accounting for
overlapping between them or the influence they can exert over another (92). This concern has
been partly addressed by Enrichment Map, which groups dependent gene-sets into network
clusters, enabling researchers to quickly visualize major enriched functional themes. Enrichment
map utilizes GSEA output results and was developed as an add-on application in the Cytoscape
software (96). However, the remaining unbridged gaps suggest opportunities in the field to
explore.

1.6.3

The Third Generation: Pathway Topology (PT)-Based Approaches

Beside simple gene lists, publicly available pathway databases also provide vast amount
of information about genes that interact with each other in a given pathway, how they interact
(e.g., activation, inhibition, etc.), and where they interact (e.g., cytoplasm, nucleus, etc.). ORA
and FCS methods dramatically under-utilize the knowledge that such pathways are meant to
capture. Thus, if the pathways are perturbed with new connections between the genes, so long as
they contain the same set of genes, ORA and FCS will return exactly the same results.

The key hypothesis of pathway topology (PT)-based analysis is that interactions found in
pathway topology, annotated in pathway databases, bear information for interpreting correlated
changes between pathway components. PT-based methods can be seen as extensions of the
ORA and FCS methods, as they perform along the same initial steps. The main difference
comes the use of pathway topology to compute gene-level statistics (85).
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PT-based methods that consist of multiple scoring steps, are difficult to generalize and
are beyond the scope of this dissertation. A detail overview of existing methods are published
previously (87). The most popular commercial tool that incorporates topology in the pathway
analysis

is

MetaCore (oftenly

regarded

as

GeneGO,

Thomson

Reuters, http://www.thomsonreuters.com). Here, MetaCore use only the differentially expressed
gene list without associated expression value as input for its two propriety knowledge bases: an
interaction database and canonical pathways (87).

PY-based methods have certain common limitations. One problem is that true pathway
topology is highly specific to the phenotypes and condition being studied. However, this
information is fragmented in pathway data bases (85). As annotations improve, these
approaches are expected to become more useful. Currently, there is no analysis method that
takes advantage of the information stored in all of these different pathway database sources.
Promising developments include the incorporation of multiple component types and interaction
types, each with specific properties (87).
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Figure 6
Overview of existing pathway analysis methods using gene expression data as an example. Note
that this overview is equally applicable to molecular measurements using proteomics, and any
other high-throughput technologies. The data generated by an experiment using a highthroughput technology (e.g., microarray, proteomics, metabolomics), along with functional
annotations (pathway database) of the corresponding genome, are input to virtually all pathway
analysis methods. While ORA methods require that the input is a list of differentially expressed
genes, FCS methods use the entire data matrix as input. In addition to functional annotations of
a genome, PT-based methods utilize the number and type of interactions between gene products,
which may or may not be a part of a pathway database. The result of every pathway analysis
method is a list of significant pathways in the condition under study. DE, differentially
expressed. This figure is reproduced based on previously published figure (85).
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With efforts to understand vast amount of data generated by high-throughput
experiments, thousands of computational pathway analyses tools have been developed over the
better part of the last two decades. Each tool has pros, cons and even ‘niche’. Thus, it is
important for biology researchers to understand the basis of how they are built and be conscious
of the limitations when applying these methods on their high-throughput data.

1.8 Papillomavirus-related cutaneous squamous cell carcinoma
Papillomaviruses (HPVs) are small non-enveloped icosahedral viruses that infect the
keratinocytes of skin and mucosa. HPVs are represented mainly by the beta and gamma genera,
which are widely present in the skin of normal individuals. In recent years, the impact of viruses
to cutaneous oncogenesis has increasingly gained recognition. Cutaneous HPVs that belong to
the beta genus (β-HPV) have been found to act as co-carcinogen with UVR. Mechanistic
studies have previously shown that UV can trigger the promoter activity of the cutaneous types
HPV5, 8, 20, and 77 (97, 98). Exposure to UV could also favor replication of β-HPV types by
inducing local immunosuppression (99). Furthermore, immunosuppressed individuals show a
markedly increased incidence of β-HPV–positive SCC (100).

1.9 Dissertation outline
It is well accepted that miRNAs are often deregulated and plays major roles in tumor
development. The aim of this dissertation is to better understand the role of miRNAs and their
targets in cuSCC development in order to identify biomarkers for prediction and prevention of
this second most common skin cancer.
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Chapter one provides a general introduction to cuSCC risks, genomic backgrounds,
mouse models, details of miRNA biogenesis and available miRNA prediction tools. We also
discuss the method of pathway analyses that were used on our next-generation sequencing data.
In chapter two, we provide information on methodologies and materials used in this study. In
chapter three, we investigated the transcriptomes of UV-exposed skin, wound healing skin and
cuSCC tumors based on the knowledge that cuSCC mostly arise from chronic UV-exposed skin
and wound areas. We discovered that their transcriptomes overlap significantly. Thus, we were
able to use common transcriptomic features shared by these three tissues to identify potential
candidates for biomarkers evaluation. In chapter four and chapter five, we characterized the
functions of important miRNAs in cuSCC and identified novel functional targets that are
regulated by the miRNAs.
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Chapter 2: Materials and methods
Cell Culture
Normal human epidermal keratinocytes (NHEK) were purchased from Lonza and
maintained in KGM-Gold Keratinocyte Basal Medium (Lonza). SRB1, SRB12, and COLO16
were a gift from Dr. Jeffrey Myers UT MD Anderson Cancer Center (Houston, TX). SCC
IC1, SCCT1, SCCT2, SCCT3, SCCT8, SCRDEB2, SCRDEB3 and SCRDEB4 were provided
by Dr. Andrew South at Thomas Jefferson University (Philadelphia, PA). HaCaT cells, an
immortalized human keratinocyte line cell was obtained from Dr. Norbert Fusenig at German
Cancer Research Center. CuSCC cell lines were maintained in DMEM/F12 (1:1), supplemented
with with 10% FBS, RM+ supplement (101) and 1% pen/strep. All lines were STR profiled to
confirm distinct identities.

Quantitative RT-PCR
miRNAs and mRNAs were detected by Taqman quantitative reverse transcription PCR
(qRT-PCR) method. Expression of miRNAs were normalized by RNU6B. Expression of
mRNAs were normalized to GAPDH. All primers were purchased from Thermo Fisher, USA
(Cat. # 4427975, Assay ID 000480).
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Western blot analysis

50µg of total protein were electrophoresed on 10% SDS-PAGE gel and transferred to
PVDF membrane as previously described (6, 127). Blots were then probed with antiΔNp63

(619002,

Biolegend,

1:500),

E-cadherin

(3195,

Cell

Signaling, 1:1000),

Vimentin (ab92547, Abcam, 1:1000), Twist1 (sc-81417, Santa Cruz, 1:250), Lef1
(2230S, Cell Signaling, 1:1000), Snail (3879S, Cell Signaling, 1:1000), Zeb (sc-10572,
Santa Cruz, 1:500), Smad2 (sc-101153, Santa Cruz, 1:500), Smad3 (9523S, Cell Signaling,
1:1000), phospho-Smad2 (ab53100, Abcam, 1:500), and phospho-Smad3 (9520S, Cell
Signaling, 1:500) overnight at 4oC. Horseradish peroxidase conjugated- secondary
antibodies against either murine or rabbit IgG (Jackson lab) were incubated with the blots
for 1 hour at room temperature. Actin (A5060, Sigma) or Hsp90 (ab13495, Abcam) was
used as loading control. Detection was performed using ECL Plus Kit (Amersham) or
Licor system.

Apoptosis assay
TMRE (Invitrogen) was used as a measure of mitochondrial membrane potential,
Annexin V-FITC or Annexin V-APC (Invitrogen) as a probe for apoptosis, and Cytox Blue
(Invitrogen) as an indicator for dead cells. At 6, 24, or 48 hours post-irradiation, both floating
and adherent cells were collected and stained with TMRE, Annexin V and Cytox Blue. Data
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were collected and analyzed using a flow cytometer (FACScalibur, Becton Dickinson) and
FlowJo Software (Tree Star). Data were analyzed and charts were plotted using GraphPad
Prism software.
Confluence-based proliferation aassay
0.2x104 cells per well were plated onto 96-well plates. The plates were read with the
IncuCyte (Essence Bioscience) every 6 hours for 96 hours. Cell confluency or density was
measured using IncuCyte Zoom software.
Overexpression and inhibition of miRNA in cuSCC cells and keratinocytes
5x105 cells per 60 mm dish were transfected with 40 nM microRNA inhibitors
(ThermoFisher) or 3 nM microRNA mimics (ThermoFisher) using Lipofectamine RNAi
Max (Invitrogen) according to manufacturer’s protocol. The cells were collected 48
hours post-transfection for further analysis. The microRNA inhibitors used to target
microRNAs are as followed: miR-21-5p, miR-21-3p, miR-181a-5p and negative control
(4464077) (ThermoFisher). The microRNA mimics purchased from ThermoFisher are
miR-21-5p, miR-21-3p, miR-181a-5p
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and negative control mimics (4464058).
Lentivirus-based GFP-tagged vectors for hsa-miR-181a (lenti-miR-181a OE) or scramble
control (lenti-miR-00 control) were purchased from System Biosciences (SBI) lenti-miRNA
vector bank. Transduction efficiency was assessed by GFP intensity and Taqman qRT-PCR.

Overexpression and depletion of TGFΒR3
To overexpress TGFbR3, we purchased pDONR223-TGFΒR3 (Addgene, plasmid #
23478) donor vector which contained TGFΒR3 ORF. Then, the TGFR3 ORF was cloned into
pcDNA4.1/V5 expressing vector using Gateway technique. All vector sequences were validated
by Sanger sequencing. TGFΒR3 expression was validated by western blot.
To deplete TGFR3, we use GIPZ Human TGFR3 shRNA (GE Dharmacon, Clone ID
V3LHS_352448 and V3LHS_352450). GIPZ non-silencing lentiviral shRNA (GE Open
Biosystems, Cat. # RHS4348) was used as control. The shRNA lentivirus was prepared with
293T cells and psPAX2/pVSV.G packaging plasmids, and then was transduced to target cells.
Following transduction, cells were puromycin-selected and sorted to obtain cells with high-level
suppression TGFR3 suppression were validated by Taqman qRT-PCR.

Trans-well Invasion Assay
Cells were treated with mitomycin C 2 hours prior to the assay, then 4.5 x 105 cells were
suspended in serum-free media and seeded on a 8µM pore size control insert (Corning, Cat. #
08-774-162) or the insert coated with matrigel (Corning, Cat # 08-774-122). Complete media
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contain 30% FBS was added to the lower compartments as a chemo-attractant for cells.
Thereafter, cells were allowed to move for 48 hours. Cells remaining on the upper side of the
membrane were removed. Those that invaded to the bottom side of the membrane were fixed
and stained with Diff-Quik Stain Set (Siemens B4132-1A). The membranes were air-dried and
mounted for photography. Cells from ten random fields were counted.

miRNA in situ hybridization (ISH)
In situ hybridization was conducted by the MD Anderson Center for RNA interference and noncoding RNAs. Skin squamous cell cancer tissue arrays (Cat # SK 801b and # SK 802a) were
purchased from US Biomax, Inc. (Rockville, MD).

Plasmid construct and luciferase reporter assay
The pEZX-MT05 expression vector harboring the human TGFR3 3’UTR cDNA
(GeneCopoeia, Cat. # HmiT066530) was used as DNA template. Site-directed mutagenesis was
carried out using the QuickChange II XL Site-Directed Mutagenesis Kit (Catalog #200521,
Agilent Technologies), following the Manufacturer’s instruction. The mutagenic primers were
synthesized by IDT and the oligonucleotide sequences of these primers are listed in Table X.
The success of the designed mutations was verified by DNA sequencing.

HaCaT cells were transfected with wild-type and mutant reporter vectors along with
scrambled control. 72 hours after transfection, the cell culture medium was collected for the
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assay. The luciferase reporter assays were performed according to the manufacturer’s guidelines
for the Secrete Pair Dual Luminiscence Assay Kit. Luciferase activity was normalized to
secreted alkaline phosphatase.

Soft agar and colony formation assays
Following plating of bottom agar (0.6% Bacto Agar) with media we plated 2500 to
10,000 cells per well and they were embedded in top agar (0.3%) and plated in 24-well plates.
Control or lenti-miR-overexpression media was replaced every 48 hr for 4 to 6 weeks. Cell
colonies were stained with 1% crystal violet, imaged and quantified.

Protein extraction and Western blot analysis
Protein lysates were prepared in RIPA buffer (Sigma, Cat # R0278) supplemented with
Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Scientific, Cat #1861281). Primary
antibodies were obtained from Cell Signaling and Thermo Scientific. Westerns were imaged
using the Licor Odyssey CLx system.

Animals and in vivo model of human cutaneous squamous cell carcinoma
NOD CRISPR Prkdc Il2r gamma (NCG) mice (6 to 8 weeks old; Charles River) were
housed and monitored in our Animal Research Facility. All experimental procedures and
protocols had been approved. RDEB2 cells were transfected with control inhibitor and miR181a inhibitor. 24 hours post-transfection, cells were trypsinized for xenografting. Mice were
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subcutaneously inoculated with 3 x 106 SCC RDEB2 cells. Once tumors become palpable,
measurement was taken every other day. Mice were sacrificed 11 days after inoculation.

mRNA-Seq analysis
The mRNA-seq paired-end reads were aligned to the human reference genome,
GRCh37/hg19, using the TopHat2 alignment software (102, 103). The overlaps between aligned
reads and annotated genomic features, such as genes/exons were counted using HTSeq software
(104). Hierarchical clustering analysis, using the Pearson correlation coefficient as the distance
metrics and the complete linkage, and principal component analysis (PCA) were performed
using the R statistical system. Genes significantly different between the control and different
time points of acute UV treatment were determined using the R package DESeq (105). Since
multiple genes were tested simultaneously, the Benjamini-Hochberg method was used to control
false discovery rate (FDR). For further integration of mRNAs and miRNAs, and detection of
enriched transcription factor targets, we used a cutoff of Q-value<0.05 and fold change
exceeding 1.25x.

smallRNA-Seq Analysis.
This work was performed with collaboration with laboratory of Dr. Preethi Gunaratne,
PhD (University of Houston, Biology & Biochemistry). As previously described (17), Illumina
small RNA adapter sequences were trimmed from the reads, and reads of length below 10nt or
ending in homopolymers of length 9 nt or above were discarded. Total usable number of reads
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for each sample was calculated. The reads were mapped to the miRBase (106) reference using
BLAST; the abundance of each expressed microRNA was quantified as a fraction of the usable
reads, and expressed as parts per million We determined differentially expressed microRNAs
imposing a fold-change of 1.25x and t-test comparison (p<0.05) using the R statistical system.
We employed principal component analysis (PCA) to examine sample structure; further
visualization of microRNA significant in one or multiple comparisons was carried out using the
R statistical system.

Integrative mRNA-miRNA functional pair analysis.
We determined enriched miRNA-mRNA pairs using the SigTerms methodology.
Essentially, by applying a one-sided Fisher exact test and using the TargetScan (107) predicted
microRNA targets, we determined the miRNAs for which the gene targets are significantly
enriched (FDR-adjusted q<0.25) in the gene signature. Finally, we determined the conserved
enriched miRNAs and the conserved miRNA-mRNA pairs conserved with respect to acute UV
treatment.

TMT-base proteomics
Sample Preparation. Cells were lysed in denaturing lysis buffer containing 8M urea, 20 mM
HEPES (pH 8), 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate and 1 mM βglycerophosphate. A Bradford assay was carried out to determine the protein concentration.
Equal amount of heavy and light proteins were mixed together. The mixed proteins were
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reduced with 4.5 mM DTT and alkylated with 10 mM iodoacetamide. Trypsin digestion was
carried out at room temperature overnight, and tryptic peptides were then acidified with 1%
trifluoroacetic acid (TFA) and desalted with C18 Sep-Pak cartridges according to the
manufacturer’s procedure.
TMT Labeling. 400 microgram of peptide from each sample was labeled with TMT reagent.
The label incorporation was checked by LC-MS/MS and spectral counting. 98% or greater label
incorporation was achieved for each channel. The 6 samples were then pooled and lyophilized.
High pH Reversed Phase Peptide Separation. After lyophilization, the peptides were redissolved in 400 micro liter of 20 mM Ammonium Formate, (pH 10.0). The high pH reversed
phase separation was performed on a Xbridge 4.6 mm x 100 mm column packed with BEH C18
resin, 3.5 µm, 130Å. (Waters) The peptides were eluted as follows: 5% B (5 mM Ammonium
Formate, 90% acetonitrile, pH 10.0) for 10 minutes, 5% - 15% B in 5 minutes, 15-40% B in 47
minutes, 40-100% B in 5 minutes and 100% B held for 10 minutes, followed by re-equilibration
at 1% B. The flow rate was 0.6 ml/min, and 24 concatenated fractions were collected. Speedvac
centrifuge was used to dry the peptides.
LC-MS/MS. A nanoflow ultra high performance liquid chromatograph (RSLC, Dionex,
Sunnyvale, CA) coupled to an electrospray bench top orbitrap mass spectrometer (Q-Exactive
plus, Thermo, San Jose, CA) was used for tandem mass spectrometry peptide sequencing
experiments. The sample was first loaded onto a pre-column (2 cm x 100 µm ID packed with
C18 reversed-phase resin, 5µm, 100Å) and washed for 8 minutes with aqueous 2% acetonitrile
and 0.04% trifluoroacetic acid. The trapped peptides were eluted onto the analytical column,
(C18, 75 µm ID x 25 cm, 2 µm, 100Å, Dionex, Sunnyvale, CA). The 90-minute gradient was
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programmed as: 95% solvent A (2% acetonitrile + 0.1% formic acid) for 8 minutes, solvent B
(90% acetonitrile + 0.1% formic acid) from 5% to 38.5% in 60 minutes, then solvent B from
50% to 90% B in 7 minutes and held at 90% for 5 minutes, followed by solvent B from 90% to
5% in 1 minute and re-equilibrate for 10 minutes. The flow rate on analytical column was 300
nl/min. Sixteen tandem mass spectra were collected in a data-dependent manner following each
survey scan. Both MS and MS/MS scans were performed in Orbitrap to obtain accurate mass
measurement using 15 second exclusion for previously sampled peptide peaks..
Data Analysis. MaxQuant (version 1.5.2.8) was used to quantify the TMT reporter ion
intensities (108). The MaxQuant output was normalized with modified iterative rank-order
normalization algorithm (109).
Statistical analyses

All biological experiments were repeated at least three times. Numerical data were
analyzed using a one-way analysis of variation. The statistical significance between treatments
was assessed by one-tailed Student's t-tests or Paired Wilcoxon tests.
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Chapter 3: Integration of transcriptomic data identifies UV
exposure and wound-related biomarkers of cutaneous squamous
cell carcinoma
3.1 INTRODUCTION
Skin is the largest organ in the body in terms of surface area and plays vital roles in
protecting the skin from potential environmental risks. Skin cancer, 20% of which is cutaneous
squamous cell carcinoma (cuSCC), is the most common malignancy in the United States.
Because its incidence is rapidly increasing, cuSCC poses as a significant public health and
economic burden (110). UV radiation is recognized as the main etiological agent that stimulates
initiation and progression to sporadic cutaneous squamous cell carcinoma (19, 111). Although
not as common, a subset of high-risk cuSCC, which occurs in chronic wound area in recessive
dystrophic epidermolysis bullosa (RDEB) patients, is more lethal. In fact, metastatic cuSCC is
the main cause of death among RDEB patients (112). Since UV exposure and wounding are the
two main factors that lead to cuSCC initiation, study of the acute molecular dermal responses
shared by them can be beneficial to establish solid cuSCC prevention strategies.
UV exposure triggers immune response and causes multiple alterations to the
composition and architecture of the dermal extracellular matrix (ECM) (113). In melanoma, UV
radiation induced the expression of FAP through transforming growth factor-b1 (TGF-b1)
release, which mediated ECM degradation and enabled tumor dissemination (114). Similarly,
non-healing RDEB wounds, precursors of cuSCC, are characterized by increased inflammation
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and high TGF-b1 activity (112). A causal relationship between UV exposure and wound healing
was highlighted by the benefit of UV irradiation in wound care. Beside germicidal effect, UV
light exposure induced release of cytokines, growth factors and fibronectin, which enhance the
wound healing process. A few clinical and animal studies have shown that low dose UV
treament is effective in managing acute and chronic wounds (115). Even so, the similarity in UV
exposure and wound healing response and how that can be employed to prevent cuSCC
initiation were not reported.
In the current study, using miRnome and transcriptome profiling in acute UV-exposed
human skin, we first integrated differentially expressed miRNAs and mRNAs in functional pair
analysis. We further predicted significantly enriched biological pathways related to acute UV
exposure using GSEA (93). We then integrate miRNA and RNA profile of acute UV-exposed
skin to equivalent published profiles of wounding skins (116, 117). Our combinatorial analyses
show for the first time that acute UV-exposed skin (at 24h) and wounding skin (at 3 day) share
remarkable resemblances in their miRNA and RNA profile. GSEA showed that ECM
remodeling pathways and GPCR related pathways were positively enriched while while PPAR
activity decreased. Finally, we compare the miRnome and transcriptome of acute UV-exposed
skin and wound to those of cuSCC. We found that not only differentially expressed genes from
these 3 tissues overlap but they also share similar enriched pathways.
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3.2 RESULTS AND DISCUSSION
3.2.1 Identification of acute UV-exposed differentially expressed genes and microRNAs in
unexposed human skin
UV radiation is a complete carcinogen that can initiate genetic mutations in human skin
(19, 111, 118). Additionally, UV can trigger genome-wide transcriptional instability that affects
thousands of genes. Many studies of UV-induced transcriptome have focused on in vitro
approach where cultured human primary keratinocytes were irradiated with UVB (119). These
approaches did not reflect the actual systemic response of human skin to UVR nor did they
closely mimic the solar spectrum in reality. To address these issues, we interrogated normally
sun-protected human buttock skin after an acute does of two MED of solar stimulated light
(SSL). We then obtained the snap frozen whole skin samples pre- and post-UV in 8 healthy
subjects with similar types of skin (Fitzpatrick skin type II or III). The solar simulator delivered
8.7% of UVB and 91.3% of UVA (120) and the average ( ± standard error) dose delivered was
4.6 ± 0.5 J/cm2 of UVA and 51.5 ± mJ/cm2 of UVB.
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Figure 7
Study pipeline of integrating existing transcriptomes of UV-exposed skin, cuSCC tumors and
public transcriptomic data sets of wound healing skin

RNA-Seq and microRNA-Seq was used to measure the changes in genes and microRNA
expression at 6 hours and 24 hours post-SSL. The data were represented as the fold change (FC)
in transcript levels, calculated by dividing the average read counts in the UVB group by those in
control (pre-SSL) for each gene. The total number of differentially expressed genes and
microRNAs at 6 hour and 24 hour post-SSL were reported in Table 4. The differentially
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expressed microRNAs were reported in Appendix 1 and 2. We found that oncomiR miR-21 was
highly expressed (miR-21-3p: 4.9-fold, p-val = 8.65E-07 and miR-21-5p: 1.96-fold, p-val =
4.84E-05) in 24 hour post-SSL human skin which agreed with previous studies where miR-21
were shown to be induced by UV irradiation in skin and cultured keratinocytes (121) (122)
(123). Noticeably, inflammatory miR-223 which involved in rheumatoid arthritis and proriasis
progression were most significantly upregulated (7.7-fold, p-val = 5.5E-09) in 24 hour post-SSL
human skin. As an oncomiR, miR-223 promoted breast cancer cell invasiveness (124) and
stimulated proliferation, migration and invasion of gastric cancer cell lines (45). Since the
functions of miR-223 in UV-induced skins or skin cancers are unknown, this miRNAs can
potentially be further explored.
Timepoints

Total

Up-regulated

Down-regulated

Differentially expressed genes
6 hour post-SSL

767

552

215

24 hour post-SSL

3021

1633

1388

Differentially expressed miRNAs
6 hour post-SSL

5

1

4

24 hour post-SSL

89

50

39

Table 4
Differentially expressed miRNA gene counts among different conditions

47

We were interested in identifying functional miRNA-mRNA pairs that were regulated by
UV exposure. Given that miRNAs function by suppressing their target genes, we used
functional pair analysis method where upregulated miRNAs were paired with downregulated
predicted mRNA targets and vice versa. In total, we identified 45 pairs of upregulated miRdownregulated mRNAs and 37 pairs of downregulated miRs- upregulated mRNAs.
To investigate the effect of acute UV exposure through miRNAs on the molecular
pathways, we use paired target mRNAs in GSEA C2 canonical pathway analyses. Here, the 5
highest upregulated miRNAs and their downregulated predicted target genes were found to be
involved in Immune System, Signaling by GPCR and Matrisome pathways. Interestingly, 5
highest downregulated miRNAs and their upregulated predicted target genes were also found to
be involved in the same mentioned pathways (Figure 8). These pathway analyses suggested that
in acute UV-exposed human skin, Immune System, Signaling by GPCR and Matrisome
pathways were important and were indirectly regulated by miRNAs.
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Figure 8
Integrated functional pair analyses reveals canonical pathways regulated by differentially
expressed miRNAs and their predicted targets
3.2.2

Integrated analysis revealed correlation in the microRNA and mRNA expression

between acute wounding skin and UV-exposed skin
SCC can arise from chronic wounds in epidermolysis bullosa (EB) individuals who are
clinically characterized by generalized skin fragility, blistering of mucous membranes and
compromised wound healing (125). With an effort of using integrated analyses as a solid
foundation for better target prediction for cuSCC prevention, we sought to compare the
transcriptome of acute UV-exposed skin with acute wound-healing skin and cuSCC tumors. The
rationale is that cuSCC tumors can arise from chronic UV-exposed skin and chronic wounds.
To address this, we used previously published data that showed miRNAs dynamic
changes during the inflammation phase of human skin wound healing (116). This Taqman
MicroRNA low-density array data set was acquired from 5 healthy donors at 0 hour and 24
hours after injury (116). Interestingly, we found that the expression pattern of miRNA in acute
UV-exposed skin was strongly correlated with acute wound healing skin at 24 hour time point
(Figure 9). Inflammatory miR-223 is the highest increased miRNA in both data sets after 24
hour, suggesting strong inflammatory response at this time point in following UV-exposure and
injury. Among the upregulated miRNA, miR-132 has been extensively characterized in woundhealing but not in UV response. This correlation suggests that published data in wound healing
studies can be used as reference for UV response studies. Complete data on miRNA expression
can be found in Appendix 1 and 2.
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Figure 9
Transcriptome and miRNAome of UV-exposed skin, wound healing skin and cuSCC show
significant similarity. (A) Comparative miRNA expression level analysis between UV-exposed
skin and wound healing skin. (B) Comparative gene expression level analysis between UVexposed skin and wound healing skin. (C, D, E) PCA of transcriptome of UV-exposed skin,
wound healing skin and cuSCC.
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To study whether the mRNA expression of UV-exposed skin, wound healing skin and
cuSCC tumors share the similar correlation as miRNA, we again used another published
transcriptomic data set on wound healing skin (117). This study employed 8 burnt patients who
underwent skin grafting. Their skins were biopsied immediately before and after harvesting and
during the wound healing process 3 and 7 days thereafter. The biopsied tissues were subjected
to genome-wide microarrays. We used data from 3-day wound healing since it shows strong
transcriptomic correlation with UV-exposed skin and cuSCC tumors. Overlapping analyses
showed significant overlap in differentially expressed genes among three data sets (Figure 9).
Specifically, 84% of DE genes in UV-exposed skin overlapped with DE genes in cuSCC. 87%
of DE genes in wound healing overlapped with DE genes in cuSCC (Table 5).

Data set

DE genes in DE genes in DE genes in
UV
1047)

Overlap percentage among DE genes in 3 data 60%

(n= Wound

cuSCC

(n= 3673)

(n= 4354)

17%

14%

sets (n = 630)
Overlap percentage between DE genes in UV 70%

20%

and Wound (n =727)
Overlap percentage between DE genes in

87%

73%

cuSCC and Wound (n =3184)
Overlap percentage between DE genes in 84%
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20%

cuSCC and UV (n =884)

Table 5
Overlapping gene counts among UV-exposed skin (24 hour post-SSL), wound healing skin (3
day post-injury) and cuSCC tumors
To better visualize the overall directional changes in 3 data sets, we performed principle
components analysis (PCA). The data projected the 2 distinguished clusters of the UV-exposed
skin, wound healing skin and cuSCC tumors and their normal control counterparts (Figure 9).
To confirm, we projected the transcriptome of normal skin, AKs and cuSCC tumors and
observed that the transcriptome of AK spanned those of normal skin and cuSCC. This
observation agreed with previous study from our lab where we showed the transcriptomic of AK
spanned the spectrum of normal skin to cuSCC (17). Overall, these results showed that there
was a strong unprecedented correlation between the mRNA and miRNA expressions of UVexposed skin, wound healing skin and cuSCC tumors.

3.2.3

Pathway analyses revealed correlation in the microRNA and mRNA expression

between acute wounding skin and UV-exposed skin
The global functional impact of UV-exposure vs. wounding vs. cuSCC on skin was
determined by using 3 approaches: integrated GSEA analyses (Figure 10), upstream regulator
predictions through IPA (Figure 11), and canonical pathways prediction also through IPA
(Figure 11). Using pathway analyses with different algorithms and annotations allows us to
better select central and key pathways that are being affected. IPA determines overlaps between
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the provided gene lists and the curated databases, looking for overlaps that are bigger than that
expected by random chance (94). In contrast, GSEA is a tool that uses every data point in its
statistical algorithm (126) (93). Genes are ranked by from most up-regulated to most-downregulated. The two rank metrics commonly used are p-value and fold-change. The test assess
whether ember of a gene set appear enriched at one end of the profile. To test enrichment,
GSEA performs permutations of the profile, calculating the enrichment of the gene set 1000
times or more to estimate p-value empirically (126) (93).

Figure 10
Canonical pathway analyses revealed important common pathways in UV-induced skin, wound
healing skin and cuSCC tumors (q=0.05). Each circle represents a gene set. Each circle is
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divided into three sections which represent one of three dataset. Blue color represents pathway
downregulation. Red color represents pathway upregulation.

When using integrated GSEA using the C2 canonical pathway gene set, we sought to
identify unique and common pathways affected by acute UV-exposed skin, wound healing skin
and cuSCC tumors. We focus on the common pathways because these are the pathways that
were modified following UV-exposure and wound-healing that persisted in cuSCC tumors. We
reason that by focusing on these pathways, we can identify ways to predict early development of
cuSCC. Here, we observed that ECM related pathways, GPCR signaling, Cytokine and
Chemokine signaling, immune system signaling and Cell cycle signaling were significantly and
positively enriched. This suggested that these pathways were activated in acute UV-exposed
skin, wound healing skin and cuSCC tumors.

Using IPA canonical pathway analysis, although we were able to detect unique and
common pathways, we decided to focus on the common pathways modified in acute UVexposed skin, wound healing skin and cuSCC tumors because of the above rationales.
Unsurprisingly, we found that p53 signaling was activated (Figure 11). Immune response
pathways such as Oncostatin M signaling, Interferon signaling, acute phase response signaling
were activated (Figure 11). The IPA upstream regulator analysis examines how many known
targets of transcription regulator are present in the provided data sets with the direction of
change taken into consideration. Here, upstream regulator predicted that in cuSCC tumors, there
was an activation of tumor promoters while an inhibition of tumor suppressors (Figure 11). Two
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transcriptional factors that were commonly predicted in three data sets were OSM and TNF-a
(Figure 11).

Figure 11
Ingenuity pathway analysis (IPA) identifies deregulation of Oncostatin M pathways and
suggests possible important role of OSM and TNF upstream regulators. (A) Unique and
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common IPA canonical pathways shared by three data sets. (B) Identified upstream regulator in
three data sets.
3.2.4 Oncostatin M is a potential marker for cuSCC early development
Oncostatin M supports diverse homeostasis processes including liver repair, cardiactissue remodeling, and hematopoiesis. However, overproduction of OSM is thought to promote
a variety of pathologies, including skin and lung inflammation, and several forms of cancer
(127) (128). Nevertheless, the role of OSM in cutaneous squamous cell carcinoma has remained
unclear (127) (128). Here, in cuSCC tumor, pathway mapping using GeneGO suggested that
OSM can exert its effect through TIMPs and MMPs to regulate ECM remodeling; through
Cyclin D1 and VEGF to modulate growth and through CCL2 to regulate inflammatory response
(Figure 12).
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Figure 12
Oncostatin M downstream networks. GeneGO pathway generator identify possible downstream
molecular targets and cellular processes regulated by Oncostatin M.

Next, we sought to validate whether expression of OSM and its downstream targets
affect survival in SCC. We used TCGA data from HNSCC with TP53 mutation because
genetically, this type of carcinoma most closely related to cuSCC. The Kaplan-Meier survival
curves showed that high OSM expression related with shorter overall survival time in
comparison with low OSM expression (p-value = 0.005) (Figure 13). In addition, survival
analysis based on expression of Oncostatin M signaling downstream upregulated targets
ACTA2, MMP1, CCL2 showed that high expression of these genes related to shorter overall
survival time (Figure 14, Error! Reference source not found.) in HNSCC patients with TP53
mutation.
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Figure 13
Kaplan – Meier survival analysis of OSM gene expression in HNSCC patients with TP53
mutation. In this cohort, high expression of OSM is associated with shorter overall survival
(High: median survival = 831 days; Low: median survival = 2033). Kaplan – Meier curves
were generated following bifurcation of gene expression at median (High: n =42, Low: n =41).
P-values were calculated according to the log-rank test.
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Figure 14
Kaplan – Meier survival analysis of ACTA2, MMP1, CCL2 gene expression in HNSCC patients
with TP53 mutation. In this cohort, high expression of OSM is associated with shorter overall
survival (High: median survival = 1057 days; Low: median survival = 1962). Kaplan – Meier
curves were generated following bifurcation of gene expression at median (High: n =42, Low: n
=41). P-values were calculated according to the log-rank test.
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3.3

DISCUSSION
UV exposure is the most important risk for skin carcinogenesis. Exposure to UV radiation

in early age increased childhood melanoma risk (129). In this chapter, we showed that the
transcriptomic deregulation observed in cuSCC was induced early in UV-exposed skin and
wound healing skin, which are the two main preconditions of cuSCC development. We show
molecular evidences for the transcriptomic correlation between UV-exposed skin and wound
healing skin using multiple gene set analysis tools. Previously found, moderate and repeated
doses of UV can enhance wound healing process because of its antimicrobial effects (115).
Patients with skin injury has greatly benefited from UV light therapy following skin wounding
(130). Besides that, UV and wounding has been studied as two separate events even though they
might lead to the same consequences of non-melanoma skin cancers. Our findings provide
unique evidences showing that transcriptomes of UV-exposed skins and wounded skins largely
overlap. Our study also provides rationales for future studies in integrating existing findings in
UV radiation and wounding.
UV-exposure and skin injury triggers similar responses in human skin transcriptomes
reflecting through several pathways. First, there is activation in pathways associated with
inflammatory responses. Although inflammation is the second stage of wound healing, it is
unexpected that we observed similar response in acute UV-exposed skin. These inflammatory
responses might have resulted from the release of a variety of regulatory mediators including
cytokines and chemokines following UV-exposure or skin injuries (131, 132). Here, at the UV
irradiated sites or wounded sites, components of innate immune system such as macrophages
are also recruited. Previously known, macrophage electrotaxis is mostly dependent on Rho
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family small GTPases (133). Thus, this might be the explanation for the observed positive
enrichment of GPCR signaling that might have been precursors to macrophage recruitment.
OSM is thought to promote a variety of pathologies, including skin inflammation, and
various forms of cancer (127, 128). Our analyses using multiple data sets and pathway analysis
platforms suggested that Oncostatin M signaling, a pathway found to be modified early in UVexposed skin and wound healing with its deregulation existed in cuSCC tumors. High OSM
gene expression shows significant correlation with overall survival in HNSCC patients with
TP53 mutation, which is genetically related to cuSCC. Based on these findings, we aim to
characterize OSM functions in cuSCC in vitro. Here, our results suggest that Oncostatin M can
be further evaluated as a novel target in cuSCC treatment.
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Chapter 4: Identifying miR-21 and miR-31 in cutaneous squamous
cell carcinoma development
4.1 INTRODUCTION
miR-21 is a well-characterized oncogenic miRNA which was found to be the only
miRNA consistently overexpressed in 540 clinical samples of cancer patients (42). However,
only a handful of study has been conducted on characterizing miR-21 functions in skin
disorders. miR-21 has been linked to the pathogenesis of epidermal hyperplasia in psoriasis
through its targets TIMP-3 (134). miR-21 knockout mice show no obvious phenotype in
development or adulthood, and seem to be protected against cancer development (135, 136). In
invasive cuSCC, miR-21 is elevated and thought to induced epithelial mesenchymal transition in
cuSCC (137). It has also been shown that miR-21 inhibition increased apoptosis in A431 cuSCC
cell lines (138). In immunocompetent individuals, miR-21 and miR-31 is significantly
upregulated in their healthy skin suggesting that deregulation of miR-21 and miR-31 happens
early in cuSCC development (139).
The functional role of miR-31 is especially complex because miR-31 can have tumorsuppressive and oncogenic roles in different tumor types.

However, a handful of studies

suggested that miR-31 is oncogenic in cuSCC. A study employing A-431 cuSCC cell lines
showed that miR-31 targets RhoTBT1 and regulate cuSCC proliferation and invasion (140).
Another study determined that miR-31 regulated cell motility and colony formation ability of
tumor cells (141).
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Our data shows that while miR-21 was highly upregulated in UV-exposed skin, miR-31
has been shown to increase in the late inflammatory phase of wound healing skin (142). In
addition, our microRNA-seq data of shows that miR-21 and miR-31 were the most highly
expressed miRNAs in sporadic cuSCC, immunosuppressed cuSCC and Xeroderma
pigmentosum cuSCC (Figure). These evidences motivated us to further explore the functions of
miR-21 and miR-31 in more cuSCC cell lines and UV-induec cuSCC mouse model. In this
study, we hypothesize that deregulation of miR-21 and miR-31 collectively plays a role in the
development of cuSCC. We investigated the expression levels of miR-21 and miR-31 in cuSCC
cell lines; examine their possible functions and the targets through which they exert their
functions.

4.2 RESULTS AND DISCUSSION
4.2.1 Expression of miR-21 and miR-31 in cuSCC tumors
We sought to study the miRNA-expression landscape in cuSCC tumors and normal skin
tissues derived from three different groups of patients: (1) Patients with sporadic cuSCC (n=
14), (2) Immunosuppressed patients (n= 5) and (3) Xeroderma pigmentosum patients (n= 8). We
performed RNA-Seq to evaluate the expression of miRNAs in the tumors and normal skins.
While we were able to identified upregulated miRNAs and down regulated miRNAs, we noticed
that there is substantial overlap of miRNAs in the miRNA expression spectrum of the three
patient groups (Appendix 3). Here, we found that miR-21 and miR-31 are highly up-regulated
universally in all cuSCC tumor types compared to normal counterparts. Specifically, in sporadic
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cuSCC, miR-21 increase 6.1-fold (p-value < 0.05) and miR-31 increases 9.7-fold (p-value <
0.05), compared to normal skin. Notably, several miRNAs identified from this experiment (data
shown in Appendix 3) have previously been known to regulate various biological processes
related to cuSCC; these include upregulated miR-135b (143-145) and downregulated miR-211
(146-148).

Figure 15
miR-21 and miR-31 were highly upregulated across cuSCC subtypes. X-axis, Y-axis and color
represent miRNA expression levels (log2 fold change) in UV-driven cuSCC, cuSCC in
immunosuppressed patients and Xeroderma pigmentosum, respectively. Graph was generated
using Plotly open source tool (https://plot.ly/).
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Next, we then used qRT-PCR to validate the expression level of miR-21 and miR-31 in normal
human keratinocytes (NHEK) and 10 cuSCC cell lines derived from different types of cuSCC
tumors (See Introduction). We found that majority of cuSCC cell lines have elevated miR-21
and miR-31 expression level compared to NHEKs (Figure 17). Cell line that has the highest
miR-21 expression level compared to NHEK is SCCIC1 (4.4-fold upregulation). Cell line that
has the highest miR-31 expression level compared to NHEK is SCC IC1 (13.8-fold
upregulation). Taken together, the results of our RNA-seq and qRT-PCR demonstrate that miR21 and miR-31 expression level are highly upregulated in cuSCC cell lines and cuSCC tumors
of different origins, suggesting the important roles of miR-21 and miR-31 in cuSCC
development.

Figure 167
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miR-21 and miR-31 expression level in cuSCC cell lines. Taqman qPCR experiments were
performed in three biological replicates. Cells were group in three based on miR-21 and miR-31
expression level. Graph shows correlation between miR-21 and miR-31 in each cuSCC cell
lines.
4.2.2 Modulation of miRNA expression levels in cuSCC cell lines
In order to study the effect of miR-21 and miR-31, we first established conditions for
overexpression and knockdown of both miRNAs. To overexpress, we have used locked nucleic
acid (LNA) modified oligonucleotides and transiently transfected it into cuSCC cell lines of
interest. To knockdown, we have also used LNA modified antisense nucleotide to inhibit the
expression of both miR-21 and miR-31 mature strands. The miRNA expression in testing
condition was compared to cells transfected with a mock LNA sequence. We confirmed that the
cellular level of established miR-21 and miR-31 targets were decreased following overexpression and increased with inhibition of the miRNAs (Figure ).
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Figure 18
miR-21 inhibitor increase the expression of PDCD4, its established targets by 1.7-fold based on
western blot analysis and vice versa. miR-31 inhibitor increase transcriptional level of STK40, a
published target of miR-31(149) by 2.6-fold through qRT-PCR and vice versa.
4.2.3 miR-21 and miR-31 synergistically increased proliferation in cuSCC cell lines
To determine whether miR-21 and miR-31 affects the proliferative capacity of cuSCC
cell lines, we performed proliferation assays. Cells were transiently transfected miR-21 and
miR-31 inhibitors (Thermo Fisher). After 48 hours, transfected cells were re-seeded for Incucyte
confluence-based proliferation assay. Cell proliferation was visualized and quantified using
time-lapse imaging. We observed that miR-21 inhibitor and inhibitor combination treatment
significantly suppressed cell proliferation in majority of tested cells (Figure 17). Interestingly, at
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96 hour after seeding in SCCT8, which has the high miR-21 expression level, miR-21 inhibitor
decreased its proliferation by 39% while inhibitor combination suppressed proliferation by 80%
compared to cells transfected with non-targeted control. In line with this, the cell proliferation
suppression by miR-21 and inhibitor combination was also observed in SCC IC1, SCC RDEB2
and COLO16. These data indicate that loss of miR-21 contribute to reduction in cuSCC cell
proliferation. More importantly, this suggested that miR-21 and miR-31 inhibitor can act
synergistically in inhibiting cuSCC tumor proliferation.

Figure 17
Line graphs showing result of confluence-based cell proliferation assay (Incucyte, Essen
Bioscience). Cells were seeded for proliferation assays 24 hour post-transfection with nontargeting inhibitor control, miR-21 inhibitor, miR-31 inhibitor and inhibitor combination.
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4.2.4 miR-21 and miR-31 synergistically decreased apoptosis in cuSCC cell lines
Generally, miR-21 acts as an antiapoptotic agent as it suppresses the expression of the
pro-apoptosis proteins PDCD4, PTEN, and many other (136, 150-152). Here, apoptosis analysis
was performed to investigate whether cuSCC call apoptosis could be influenced after miR-21
and miR-31 expression inhibition. We found that miR-21 inhibitor, miR-31 inhibitor and the
inhibitor combination induced apoptosis (AnnexinV positive cells) in SCCT8 cell lines by 2.59
± 0.42 – fold (p-value = 0.0138), 1.51 ± 0.28 - fold (p-value = 0.0596) , 3.53 ± 0.2-fold (p-value
= 0.0032) respectively, compared to cells transfected with non-targeted control (Figure 17). We
detected significant decrease in apoptosis in all cuSCC cell lines tested. Specifically, in RDEB2,
miR-21 inhibitor, miR-31 inhibitor and the inhibitor combination induced apoptosis by 2.73 ±
0.83 – fold (p-value = 0.0285), 1.33 ± 0.5 - fold (p-value = 0.1767), 4.03 ± 0.72-fold (p-value =
0.0067) respectively, compared to cells transfected with non-targeted control (Figure 21). In
COLO16, miR-21 inhibitor, miR-31 inhibitor and the inhibitor combination induced apoptosis
by 1.92 ± 0.55 – fold (p-value = 0.093), 1.3 ± 0.12 - fold (p-value = 0.3717) , 3.34 ± 0.7-fold (pvalue = 0.0214) respectively, compared to cells transfected with non-targeted control (Figure
21).
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Figure 18
cuSCC cells were transfected with non-targeting inhibitor, miR-21 inhibitor, miR-31 inhibitor
and control inhibitor. After 48 hours, cells were labeled with annexin V-FITC and PI was
collected on a BD FACS Canto II.

Noticeably, the combination of miR-21 inhibitor and miR-31 inhibitor showed
synergistic effect on inhibiting apoptosis in cuSCC cell lines. Specifically, in SCCT8, inhibitor
combination increased apoptosis by 27% while total apoptosis increase of miR-21 inhibitor and
miR-31 inhibitor was 45%. Taken together, this result provides indication that miR-21 and miR31 inhibitors have synergistic effect in cuSCC apoptosis. Furthermore, this data provide
additional evidence that mir-21 and miR-31 cooperatively act to promote cuSCC development.
4.2.5 Identification of novel targets for miR-21 and miR-31 in cuSCC
TMT-based detection of the proteins was carried out in the transfected SCCT8 with
either the mimics of the inhibitor against miR-21, miR-31 and both of them (Figure 22). SCCT8
was chosen based on low heterogeneity often seen in cuSCC cells and strong response to
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inhibitor treatment. We successfully detected significantly modulated proteins in three mimic
treatment groups and three inhibitor treatment groups (p-value < 0.05).

Figure 19
Design of proteomics experiments on SCCT8 to identify miR-21 and miR-31 novel targets in
cuSCC. Experiments were performed in three biological replicates.
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Figure 20
Principle component analysis of identified proteins in eight experimental conditions

We next compared the list of differentially expressed proteins from our proteomics study
to their respective list of experimentally and computationally predicted targets of both miRNAs.
Computational prediction of targets against miRNAs typically leads to hundreds of predicted
targets and is widely held to be susceptible to false positive prediction. We used consensus
prediction of targets, considering only targets commonly predicted through at least four
prediction programs including TargetScan to generate a list of targets for miR-21 and miR-31
and finally checked for the presence of these targets in our list of differentially expressed
proteins identified by proteomics. The consensus target prediction approach led to 1695 targets
for miR-21 and 2409 targets for miR-31 respectively. Since number of differentially expressed
proteins in miRNA-proteomics experiments is typically much lower than the total number of
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predicted targets, we looked for common proteins detected in our experiment and predicted as
targets. Given that miRNA functions by suppressing the expression of their target genes, we
focused on predicted miRNA targets that increased following miRNA inhibition and decreased
following miRNA overexpression. We then looked qualitatively for overlapping differentially
expressed proteins in both conditions. In the proteomics study for miR-21, we identified 42
proteins that fulfill these conditions. Here, we were able to identify that several potential
functional targets of miR-21 in cuSCC that were shown in Table 6. In the proteomics study for
miR-31, we identified 31 proteins that fulfill these conditions. Combining miR-21 and miR-31
potential target results, we found that MTMR12 and MOCS2 can be common functional targets
of miR-21 and miR-31 in cuSCC. To validate that the proteomics study were performed
properly, we confirm that a known target of miR-21, Isoform 2 of Program Cell Death Protein 4
(PDCD4) increased by 1.8-fold following miR-21 inhibitor treatment and decreased by 1.77fold following miR-21 mimic treatment, compared to their respective non-targeting controls.

Predicted
target
ANXA1
BID
CAMSAP1
GSS
GTPBP1
MTMR12
MYO1E
SUB1
TIMP2
TP53BP2

miR-21 mimic
treatment
(log2FC)
-0.43239
-0.25126
-0.204
-0.12422
-0.29233
-1.11217
-0.1127
-0.18375
-0.29589
-0.13135

miR-21
inhibitor
treatment
(log2FC)
0.272606
0.555065
0.227075
0.220859
0.256802
1.091099
0.23083
0.171702
0.411779
0.352458
74

mimic
combination
treatment
(log2FC)
-0.50538
-0.34518
-0.1243
-0.16563
-0.40514
-0.84736
-0.29566
-0.18377
-0.6813
-0.13234

inhibitor
combination
treatment
(log2FC)
0.193606
0.985248
0.483813
0.132916
0.177748
0.512323
0.147437
0.264578
0.140253
0.434275

WDR7

-0.14932

0.15522

-0.2135

0.121168

Table 6
Predicted miR-21 targets that increased following miRNA inhibitor treatment and decreased
following miRNA mimic treatment in both single and combination treatment

Predicted
target
AHNAK2
EXOC8
HECTD3
MTM1
NELFB
PGM2L1
PLEKHA1
SNRNP27

miR-31 mimic
treatment
(log2FC)
-0.3253
-0.1111
-0.44966
-0.16351
-0.15532
-0.16709
-0.1872
-0.17212

miR-31
inhibitor
treatment
(log2FC)
0.167462
0.100481
0.189476
0.130448
0.105361
0.565088
0.241933
0.398887

mimic
combination
treatment
(log2FC)
-0.24681
-0.21896
-0.27191
-0.1562
-0.16493
-0.36869
-0.10059
-0.20371

inhibitor
combination
treatment
(log2FC)
0.197691
0.219626
0.628198
0.136523
0.367473
0.616371
0.317377
0.398308

Table 7
Predicted miR-31 targets that increased following miRNA inhibitor treatment and decreased
following miRNA mimic treatment in both single and combination treatment
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Figure 21
Potential miR-21 and miR-31 targets in cuSCC were identified by using multiple miRNA target
prediction tools and integrating data from eight independent experimental conditions.

In order to identify canonical pathways regulated by miR-21 and miR-31, we use GSEA
canonical pathway analysis. Then, use Enrichment map (Cytoscape) to integrate the GSEA
output of four different conditions: cells treated with miR-21 inhibitor, miR-21 mimic, inhibitor
combination and mimic combination. We found that cell cycle pathways were enriched
significantly in cells treated with miR-21 inhibitor and inhibitor combination. Specifically,
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checkpoints activity at G1/S phase and DNA damage checkpoint was upregulated (Figure 22).
On the other hand, the inhibitor treatment seems to further decrease ECM receptor activity and
Ribosome activity (Figure 22).

Figure 22
Canonical pathway analyses revealed important common pathways regulated by miR-21 and the
combination of miR-21 and miR-31 (node cut-off: q=0.01). Each circle (node) represents a gene
set. Each circle is divided into three sections which represent one of three dataset. Blue color
represents pathway downregulation. Red color represents pathway upregulation.
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Taken together, using the integration of TMT-based proteomics analysis and
computationally predicted miRNAs targets, we were able to determine several novel functional
targets of miR-21 and miR-31 in cuSCC. Our on-going works include validating these targets in
vitro and in vivo.

4.3 DISCUSSION
The up-regulation of miR-21 in many types of tumor has been known for a long time
(153-155). In cuSCC, it was reported that hyaluronan-CD44 promoted miR-21 expression in
cuSCC progression following UV irradiation (156). In agreement with previous findings, our
data show that miR-21 and miR-31 are significantly overexpressed in three different subtypes of
cuSCC, as compared to normal skin. Although widely observed to increase in cuSCC tumors,
miR-21 and miR-31 functions in this cancer have not been characterized except for one study
which showed that miR-31 increased in cuSCC and regulated cell motility and colony formation
ability of tumor cells (141). Here, we found that the inhibition of miR-21 and miR-31
significantly suppressed cell proliferation and enhance cell apoptosis. More importantly, we
showed that miR-21 and miR-31 inhibitors functioned in a combinatorial manner, suggesting
that once validated, they can be used in cuSCC combined treatment.

Since microRNAs function through a network of target genes, it is important to identify
these targets. PDCD4 is a confirmed target of miR-21 in many types of cancer including ovarian
cancer, glioblastoma, breast cancer and many more (150, 157). Our proteomic data in SCCT8
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cell line showed that PDCD4 expression increased when miR-21 was depleted and vice versa,
which support previous findings. However, there are other proteins with higher magnitude of
change. Among several potential miR-21 and miR-31 targets identified by proteomics approach,
we identify that Myotubularin Related Protein 12 MTMR12 and Molybdenum Cofactor
Synthesis 2 MOCS2 can be the common target of both miRNAs. However, there are many other
potential candidates that have the similar magnitude of change as MTMR12. This can provide
us with challenges when identifying additional potential targets of miR-21 and miR-31. The
question is which genes are directly regulated by miR-21 and miR-31 and not as a secondary
effect of the changes in other gene expression.
Because of this, we use pathway analysis to understand important pathways regulated by
miR-21 and miR-31 and more importantly, connected these changes to potential target genes. In
another way, these analyses might tell us how some cumulative modest changes in gene
expression can lead to a more robust change in biological processes. Here, we found that cell
cycle checkpoint pathways were positively enriched in cuSCC cells treated with inhibitors.
When taking this result into the context of cell proliferation and apoptosis assay result, we
reason that the cycle checkpoints were activated due to the damage caused by miRNA inhibitor.
Taken together, this data suggests that these are the important processes where miR-21 and
miR-31 function through and that predicted targets involved in cell cycle checkpoint pathways
should be considered with greater weight.
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Chapter 5: miR-181a promotes progression of cutaneous squamous
cell carcinoma by targeting TGFβR3
5.1 INTRODUCTION
In the United States, over 700,000 cases of cutaneous squamous cell carcinoma (cuSCC)
are diagnosed annually and account for about 15-20% of all skin cancers (158). Our
understanding of the molecular and genetic events that lead to sequential progression of normal
skin (NS) to precancerous actinic keratosis (AK) to cuSCC is limited. This represents a
fundamental gap in our knowledge and understanding of this progression sequence is of
relevance to understanding cancer development and developing more effective chemoprevention
strategies. In an effort to identify transcriptional drivers of cuSCC development, we previously
genomically profiled the development sequence from NS to AK to invasive cuSCC. This effort
identified major microRNA drivers, as identified through functional pair analysis (17).

Our initial analysis suggested that miR-181a is upregulated during cuSCC development.
The miR-181 family is highly evolutionarily conserved across vertebrates with roles in
differentiation of hematopoietic cells, including lymphocytes, natural killer cells, and
megakaryocytes (159). Pathway analysis reveals that miR-181 family target genes play
important roles in cancer, axon guidance, actin cytoskeleton, MAPK signaling, and T cell
receptor signaling pathways (160).
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Several studies show upregulation of miR-181 expression in colorectal carcinoma (161),
ovarian cancer(162) and hepatocarcinoma(163) with roles in cell cycle, apoptosis, proliferation,
migration and invasion (164) through targets such as BCL2L11 (BIM) (165), BCL-2 (166),
ATM (167), and KRAS (168). In a recent meta-analysis of 21 studies involving 1685 patients,
elevated expression of miR-181a was identified as a negative prognostic molecular marker in
human head and neck squamous cell carcinoma (HNSCC)(169), a disease that closely resembles
cuSCC genomically(17, 170). Here, we define a mechanistic link between miR-181a,
susceptibility to apoptosis, cellular motility and EMT, and TGFβR3. We show that miR-181a is
able to confer several pro-tumorigenic properties upon epithelial cells, that these phenotypes are
due to the direct regulation of TGFβR3 expression, and that inhibition of miR-181a
compromises tumor growth in-vivo.

5.2 RESULTS
miR-181a overexpression is observed in cutaneous squamous cell carcinoma
First, we examined miR-181a expression in two different non-melanoma skin cancer
cohorts (Fig. 26 A and B). A tissue microarray containing 37 evaluable cases of cuSCC and 9
normal skin controls (US Biomax) was hybridized with a locked nucleic acid (LNA, Exiqon)
anti-miR-181a or nonspecific LNA anti-miR control and expression quantified within tumor
cells and normal epidermis, respectively, using the Aperio Image system. We found that miR181a was upregulated in the majority of cases, by a mean of 3.0 ± 0.5-fold (P < 0.0001,
unpaired t-test) (Fig. 26 A and B). Furthermore, Taqman qPCR showed that miR-181a-5p was
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increased in 8 out of 11 SCC cell lines when compared to normal human epithelial keratinocyte
(NHEK) (Figure 25).

Figure 23
Corellation of relative miR-181a-5p (Taqman-qRT-PCR ) expression levels in NHEK, HaCaT
and cuSCC cell lines and wound closure time.

miR-181a overexpression increases colony formation efficiency and suppresses UVinduced apoptosis.
Next, we sought to determine the potential mechanism of action of miR-181a by
assessing the pathways regulated by it. We performed microarray gene expression analysis
(Illumina BeadArray) on lenti-miR-181a HaCat (miR-181a overexpressed) and lenti-miR-00
HaCat (negative control). Ingenuity Pathway Analysis (IPA, Qiagen) revealed enrichment of
cell proliferation and cellular movement pathways (Fig. 26 C).
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HaCaT cells overexpressing with miR-181a were tested for their survival in liquid culture and
enhanced colony formation in soft agar. As a positive control we used Ha-RasV12-transformed
HaCaT cells, which readily form colonies and tumors in-vivo(171). Our results showed that
HaCaT miR-181a overexpressing cell lines have an increased capability of colony formation in
soft agar. miR-181a-overexpressing HaCaT cells produced 6.3 ± 0.6 fold more colonies (P<
0.0001, unpaired t-test) (Fig. 26D), reflective of a significant increase in anchorage-independent
proliferation.

Figure 24
miR-181a is overexpressed in cuSCC. A, ISH detection using LNA detection probe (blue) or
scramble-miR as negative control were performed on FFPE tissue microarray. Error bars
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represent the mean (+) S.E.M.; **** P<0.0001 (unpaired t-test). B, Representative images show
that cuSCC has higher miR-181a expression compared to normal skin. C, Transcriptome of
HaCaT stable cell lines overexpressing lenti-miR-181a was analyzed by IPA for their associated
molecular pathways. D, HaCaT stable cell lines overexpressing lenti-miR-181a or lenti-control
were tested for their survival in liquid culture and enhance colony formation in soft agar. Error
bars represent the mean (+) S.E.M.; **** P<0.0001 (unpaired t-test).

Exposure to UV radiation (UVR) can induce apoptosis of mammalian cells. Since UV
exposure is the primary environmental cause of skin cancer, UV-induced apoptosis represents
an important tumor suppressive mechanism. To identify a potential link between miR-181a
expression and UV-induced apoptosis, we used NHEK and HaCaT overexpressing miR-181a
and the negative lenti-miR-control. Cells were subjected to a flow cytometry-based apoptosis
assay (Annexin V) 24 hours following 750 J/m2 UV-irradiation (171). Overexpression of miR181a strongly suppressed UV-induced apoptosis in both NHEK and HaCaT cells by 86.8% ±
3.5% (P < 0.001, unpaired t-test) and 45.4% ± 2.4 % (P < 0.01, unpaired t-test), respectively
(Fig. 2A and B). Ataxia telangiectasia (ATM) is a key regulator of DNA damage signaling
pathway that activates p53 (172, 173) and a validated target of miR-181a (174). ATM regulates
cell cycle progression through phosphorylation of cell-cycle checkpoint kinase 1 (CHEK1) and
p53, and DNA damage repair through phosphorylation histone H2AX(175). Here, we showed
that ATM and p53 expression correlate conversely with miR-181a level. We also noticed that
phosphorylation of DNA damage response proteins such as CHEK1, p53 and H2AX increased
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to a lesser extent when cells with higher level of miR-181a were exposed to UV (Fig. 27C).

Figure 25
miR-181a suppresses UV-induced apoptosis and increases invasiveness of keratinocytes.
A-B, NHEK and HaCat cells were stably transfected with lenti-miR-181a or slenti-miR-control.
Cells were sham irradiated or irradiated with 750 J/m2 of UVB. Apoptotic cells were determined
by flow cytometry. Error bars represent the mean (+) S.E.M.; *** P < 0.001, ** P < 0.01
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(unpaired t-test). C, Western blots showed that overexpression impairs the proper induction of
ATM, p-p53, p-His2AX, and p-Chk1 in response to UV exposure. D-E, Trans-well invasion
assay was performed at 48 h after NHEK were transfected with control-mimic, or miR-181a-5p
mimic and RDEB2 were transfected with control-inhibitor, or miR-181a-5p inhibitor. Error bars
represent the mean (+) S.E.M.; * P < 0.05, ** P< 0.01 (unpaired t-test). F, Expression of EMTmarkers was determined by western blot in transfected RDEB2. GAPDH served as the loading
control.

miR-181a overexpression increases keratinocyte invasiveness
Because the cellular movement pathway was found to be highly enriched in miR-181a
overexpressing HaCaT cells, we asked whether miR-181a affected keratinocyte morphology and
motility and invasiveness. Interestingly, during the course of apoptosis assays, we observed that
miR-181a overexpression induced morphological changes in NHEKs, with cells adopting a
more spindled appearance. These observations suggested to us that miR-181a might also
regulate keratinocyte epithelial-mesenchymal transition (EMT).

In order to address this, we performed Boyden chamber Matrigel invasion assays using
NHEK and RDEB2 cuSCC cells (Fig. 27D and E). First, we overexpressed miR-181a in NHEK.
We observed that miR-181a-5p increased NHEK invasiveness significantly by 1.7 ± 0.2-fold
compared to non-targeting control-expressing NHEK (P < 0.05, unpaired t-test). We then
depleted miR-181a in RDEB2 cuSCC cells. Depletion of miR-181a decreased RDEB2
invasiveness by 1.7 ± 0.1-fold compared to non-targeting control-expressing cells (P < 0.01,
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unpaired t-test).

To investigate this further, we observed that this miR-181a depletion in RDEB2 resulted in
decreased of Slug (SNAI2) expression (Fig. 27F). Slug is known to be particularly relevant to
EMT in epidermal keratinocytes and our data reflect that in this context as well(176, 177).
Taken together, these data show that the loss of miR-181a can induce decreases in EMT marker
expression and cellular invasiveness.
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Figure 26
TGFβR3 is downregulated in cuSCC and is a direct target of miR-181a. A, Data obtained
by RNA-sequencing shows TGFβR3 is downregulated in cuSCC relative to normal skin. Error
bars represent the mean (+) S.E.M.; **** P < 0.05 (unpaired t-test). B, Western blot analysis of
NHEK transiently transfected with control-mimic, or miR-181a mimic showed that miR-181a
regulates TGFβR3 at the post-transcriptional level. C, Diagram of miR-181a predicted seed
regions in the WT and MUT 3’UTR of TGFβR3. D, Reporter assay in SRB1 with cotransfection
of WT reporter plasmid and control-mimic, or miR-181a-5p mimic. E, Reporter assay in
RDEB2 with cotransfection of WT reporter plasmid and control-inhibitor or miR-181a-5p
inhibitor. F, Reporter assay in HaCat, with cotransfection of WT-or MUT reporter and controlmimic, or miR-181a-5p mimic. Data represent the S.E.M. from three replicates. *P < 0.05;
**P < 0.01; ****P < 0.0001 (unpaired t-test).

TGFβR3 is a direct target of miR-181a
Since the biological significance of miRNA-driven regulation relies on the effect upon their
cognate mRNA targets, we then analyzed the predicted targets of miR-181a using
Targetscan(178), PicTar(179) and miRanda (180). The predicted target genes of miR-181a
included transforming growth factor beta receptor III, TGFβR3 which is highly relevant in skin
cancer development (Appendix table 6 shows complete target list). By using RNA-seq data
from human cuSCC samples (17), we confirmed that TGFβR3 expression is significantly
decreased in cuSCC as compared to normal skin by 1.8 ± 0.2-fold (P<0.0001, unpaired t-test)
(Fig. 3A). Western blot analysis demonstrated downregulation of TGFβR3 and increased
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phosphorylation of downstream TGF-β-pathway target SMAD2 (181) in NHEK cells
overexpressing miR-181a, consistent with upregulation of TGF-β signaling (Fig. 3B).

We then sought to address the hypothesis that TGFβR3 is a direct the target of miR-181a in
keratinocytes and we asked whether the 3’-UTR of TGFβR3 could confer direct regulation by
miR-181a. We used plasmids harboring the 3’-UTR of TGFβR3 upstream of a luciferase
reporter gene (Fig. 28C). Because of the size of the 3’-UTR, we split it into two segments
labeled “A” and “B”. Only segment “B” contained the two predicted miR-181a binding sites.
We use SCC cell line that has low miR-181a (SRB1) and high miR-181a (RDEB2) for the
reporter assay. In SRB1, the wild-type (WT) reporter plasmids were co-transfected with a miR181a mimic or, control-mimic. Reporter assays were performed 48hr post-transfection.
Compared with the control-mimic, presence of the miR-181a mimic significantly decreased the
relative luciferase activity by 3.5± 0.4-fold (P<0.005, unpaired t-test) when co-transfected with
the WT reporter plasmid for segment “B” only (Fig. 28D). On the other hand, when we depleted
miR-181a in RDEB2 and perform the same assay as with SRB1, luciferase activity increased by
1.6 ± 0.2-fold (P<0.05, unpaired t-test) (Fig. 28E).

To demonstrate the specificity of control conferred by the predicted miR-181 binding sites, we
generated the mutant luciferase reporter plasmids for segment “B”. The WT or mutant reporter
plasmid was transfected into miR-181a constitutively overexpressing HaCat cells. While the
WT reporter showed downregulation of luciferase activity these cells, the mutant reporters with
site 1 and site 2 individually mutated did not show any significant decrease in luciferase activity
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(Fig. 28E). These results show that miR-181a suppresses TGFR3 by targeting the two
predicted sites within the 3’-UTR of TGFβR3.

TGFβR3 depletion phenocopies miR-181a effect in suppressing UV-induced apoptosis
Having demonstrated that TGFβR3 is a direct target of miR-181a, we then wanted to assess the
degree to which phenotypes conferred by miR-181a-5p could be accounted for by
downregulation of TGFβR3. To this end, we determined the effects of suppressing TGFR3
expression using shRNA in NHEK. Following UV-irradiation, we performed apoptosis assay
and observed that TGFβR3 depletion suppressed UV-induced apoptosis in both NHEK and
HaCaT cells by 63.6% ± 2.1% (P < 0.005, unpaired t-test) and 73.9% ± 1.8% (P < 0.01,
unpaired t-test), respectively. Taken together, our data show that both overexpression of miR181a and depletion of TGFR3 can suppress UV-induced apoptosis in keratinocytes (Fig. 29A
and B).
TGFβR3 overexpression negates cell invasion promoted by miR-181a
Next we determined whether TGFβR3 overexpression would negate miR-181a-mediated effects
on keratinocyte invasiveness. HaCaT cells were stably transfected with lenti-miR-181a (OE) or
lenti-miR-00 (control) and subjected to Boyden chamber assays, using Matrigel-coated
membranes. Our results showed that miR-181a overexpression significantly enhanced HaCaT
invasion (2.6 ± 0.7 - fold, P<0.01, unpaired t-test). We then assessed whether miR-181ainduced enhancement of cell invasiveness could be blunted by TGFβR3 overexpression. In
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these rescue experiments, we showed that overexpression of the TGFβR3 can essentially rescue
the increased invasion nearly completely (1.3 ± 0.4-fold, P = 0.40, unpaired t-test) (Fig. 29 C
and D). These data show that for the key phenotypes of miR-181a upregulation, including
suppression of apoptosis and increased invasiveness can be attributed in large part to the
downregulation of TGFβR3.

Figure 27
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Downregulation of TGFβR3 phenocopies effect of miR-181a upregulation. A-B, Depletion
of TGFβR3 phenocopies the suppression of UV-induced apoptosis by miR-181a in
keratinocytes. NHEK and HaCat were transfected with sh-control, or sh-TGFβR3 After 24 h,
cells were sham irradiated or irradiated with 750 J/m2 of UVB. Apoptotic cells were determined
by flow cytometry. Error bars represent the mean (+) S.E.M.; *** P<0.001, ** P<0.01
(Student’s t-test). C-D, TGFβR3 overexpression negates miR-181a effects in migration and
invasion in keratinocytes. miR-181a stably expressed HaCat (lenti-miR-181a) and nontargeting control stably expressed HaCat (lenti-miR-control) were transfected with TGFβR3
expressed plasmid or vector control. Assays conducted 48 h after transfection. Error bars
show SEMs. Asterisks represent a statistically significant difference from the control
(**P< 0.01; ****P < 0.0001).

miR-181a inhibitor suppresses tumor growth in a xenograft SCC mouse model
To assess whether suppressing miR-181a expression would affect tumor growth in-vivo, we
transiently transfected RDEB2 cells with miR-181a inhibitor or control inhibitor, and then
injected them into flanks of NOD CRISPR Prkdc Il2r gamma (NCG) mice (Fig. 5A). We found
that tumors derived from RDEB2 cells transfected with miR-181a inhibitor grew substantially
more slowly, as compared to the negative control (Fig. 30B-D). By day 10, the average volume
for tumors derived from cells transfected with miR-181a inhibitor was 2.1 ± 0.5-fold (P < 0.05,
paired t-test) smaller than those derived from the cells transfected with the control inhibitor (Fig.
30B-D). Accordingly, TGFβR3 levels increased by 1.9 ± 0.5-fold (P < 0.005, two-way
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ANOVA) in tumors derived from cells transfected with miR-181a inhibitor, as compared to
control inhibitor (Fig. 30E). These results show that miR-181a plays an important role in
cuSCC progression in-vivo.

Figure 28
Inhibition of miR-181a function suppresses tumor progression in-vivo. A, Timeline of
RDEB2 SCC cell line transfection and xenograft inoculation. B, Comparison of representative
gross tumor xenografts at sacrifice. C-D, Xenograft tumor growth was significantly reduced (P
< 0.05, paired Student’s t-test, n=6 each) in tumors derived from cells transfected with miR181a inhibitor than the control inhibitor. E, TGFBR3 expression increased significantly (P <
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0.05, two-way ANOVA) in tumors derived from cells transfected with miR-181a inhibitor,
compared to control inhibitor.
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5.3 DISCUSSION
miR-181a overexpression has been associated with poor survival in oral and head and
neck squamous cell carcinoma, which supports an oncogenic function (182). Individual studies
have identified miR-181a to be upregulated in HNSCC, which is closely pathologically and
genomically related to cuSCC (183, 184). Moreover, miR-181a serves as a putative biomarker
for lymph-node metastasis of oral squamous cell carcinoma (182).

Our data show that miR-181a is significantly overexpressed in a subset of cuSCC, as
compared to normal skin. The overexpression of miR-181a significantly suppressed UV-induced
apoptosis (Fig. 2A-C), enhanced anchorage independent survival in keratinocytes (Fig. 1D), and
significantly increased invasion (Fig. 2). Importantly, we showed that many of these phenotypes
are due to the direct regulation of TGFβR3 by miR-181a (Fig. 4), which is conferred by two
sites within the 3’ UTR (Fig. 3C-F).

TGFβR3 is downregulated in various human cancers, including in HNSCC(185). In
early-stage tumors, it has a suppressive role, serving as a homeostatic regulator of the TGF-β
pathway. On the other hand, in late-stage tumors it increases TGF-β expression, promoting
tumor progression(186). The TGF-SMAD2-Slug axis has been demonstrated in oral SCC, where
SMAD2 is phosphorylated during pathway activation leading to increased migration(187).
Phosphorylated SMAD2 is also increased in cuSCC arising in higher risk organ transplant
recipients(188).

Conversely, binding of cuSCC cells to collagen VII decreases features

associated with tumor progression, with decreased SMAD2 activity(189). Also consistent with
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a tumor-suppressive role, TGFR3 overexpression has been shown to enhance TGF-β signaling
through the stimulation of SMAD-dependent signaling, resulting in upregulation of PAI-1 and
p21Cip1(190). Nevertheless, there is also data that shows deletion of SMAD2 exacerbates
cuSCC development in-vivo, reflecting the high complexity and context-dependent functions of
this pathway(191).

Our data show that TGFβR3 expression is decreased in cuSCC as compared to normal skin (Fig.
3A) and that TGFβR3 is a direct and functional target of miR-181. Furthermore, we show that
TGFβR3, as directly regulated by miR-181a, opposes TGF- β signaling, thus enhancing stressinduced apoptosis and suppressing invasiveness in cuSCC with increased miR-181a expression.
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Chapter 6: DISCUSSION AND FUTURE DIRECTION
6.1 DISCUSSION
The research in this dissertation was designed and performed with the goal of using
creative strategies to identify biomarkers for cuSCC prevention and treatment, studying how
deregulated miRNA-mRNA functions to promote to cuSCC development. The findings in this
thesis provide fresh perspective on the extent to how early changes in the expression level of
miRNA-mRNA happen in UV-exposed skin and wound healing skin, prior to the development
of cuSCC, providing solid experimental-based characterization of deregulated miRNAs
mechanism of action in cuSCC development.
In chapter three, we showed that the transcriptomic deregulation observed in cuSCC was
induced early in UV-exposed skin and wound healing skin, which are the two main prerequisites
of cuSCC development. Importantly, we identified unprecedented evidence showing that the
UV-exposed skin and wound healing skin showed significantly correlated. Even though in
clinical setting, ultraviolet therapy has been used to disinfect the wound areas promote wound
healing (115, 130, 192, 193), no studies have identified molecular correlation between UVexposed skin and wound healing skin. Furthermore, we showed that UV-exposed skin, wound
healing skin and cuSCC tumors have significant commons in their transcriptomes and canonical
pathways. Our finding suggested that Oncostatin M signaling, a pathway found to be modified
early in UV-exposed skin, wound healing and its deregulation exists in cuSCC tumors. This
showed that Oncostatin M can be further evaluated as a novel target in cuSCC treatment.
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In chapter four, we used TMT-based proteomics to identify novel targets of miR-21 and
miR-31, the two most significantly and commonly regulated in various types of cuSCC tumors
through our data. Although miR-21 and miR-31 expressions are often observed to be altered
together in many tumors (194-198), our results showed for the first time that miR-21 and miR31 exert synergistic effects in promoting proliferation and inhibit apoptosis in cuSCC. Our work
from this part of the thesis will continue with the validation and characterization of the
identified miR-21 and miR-31 targets in cuSCC cell lines and UV-induced hairless cuSCC
mouse models.
Chapter five is the continuing work to complete the project initiated by Dr. Vida
Chitsazzadeh at The University of Texas MD Anderson Cancer Center. Here, we investigated
miR-181a, a microRNA upregulated in cuSCC and induced by UV-irradiation. We showed that
miR-181a promotes migration and invasion of cuSCC cell lines through its novel target,
TGFbR3. In xenografts mouse model, miR-181a inhibitor significantly reduce tumor size. This
study offers evidence showing that miR-181a is important in promoting cuSCC development.

6.2 FUTURE DIRECTION
The discovery of miRNA genes in C. elegans and the subsequent recognition that this
family of RNAs extends throughout all multicellular organisms has provided researchers with
much more than a new class of regulatory RNAs. The substantial body of research over the last
17 years in the area of miRNA and cancer has constantly increased our knowledge base
regarding the key roles of miRNA in tumor development. In this current era of genomics and
targeted therapy, perhaps one of the more intriguing questions is how researchers can
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incorporate prediction models and existing experimental data to ultimately generate therapeutic
values that miRNA research can provide. The key answer to this question depends on how well
we understand the miRNA network of targets. It has becoming more apparent that miRNAs
systematically regulate large networks of targets instead of predominantly suppress specific
major targets. With current technology, it is possible to record even the modest change in
transcriptome and proteome following miRNA modulation. Once the target gene and protein
networks were identified, it is important to determine whether the relationship among the
components a correlation or causation. This information will help build a reliable network of
miRNA targets, in order to choose most important genes to target. Although already in mature
phase, miRNA research still has many interesting unanswered questions that can be addressed
by future research.
In the near future, the continuing work for projects in chapter 3 includes validating the
functions of OSM in cuSCC development. Here, we plan to deplete OSM and study downstream
pathways and proceses that might be regulated by OSM such as EMT and proliferation. In
chapter 4, we plan to investigate whether MTMR12 as well as other potential targets are directly
targeted by miR-21 and miR-31 in cuSCC cell lines.
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Appendix
Appendix 1
Detected miRNA in human skin at 24 hour following UV-exposure (fold change)
miRNA
hsa-miR-142-3p
hsa-miR-31
hsa-miR-132
hsa-miR-16
hsa-miR-93
hsa-miR-19a
hsa-miR-484
hsa-miR-150
hsa-miR-135b
hsa-miR-31-3p
hsa-miR-155
hsa-miR-886-3p
hsa-miR-451
hsa-miR-223
hsa-miR-652
hsa-miR-25
hsa-miR-340
hsa-miR-223-5p
hsa-miR-144-5p
hsa-miR-20b
hsa-miR-486
hsa-miR-425-5p
hsa-miR-15b
hsa-miR-142-5p
hsa-miR-539
hsa-miR-101
hsa-miR-27a
hsa-miR-1271
hsa-miR-455
hsa-miR-411

Fold change at 24h post-SSL
6.29
8.89
2.93
2.32
1.77
1.8
1.76
2.45
3.41
2.99
2.32
2.46
18.53
63.33
3.1
2.01
3.55
11.8
19.43
7.52
20.05
2.79
4.68
3.84
0.53
0.53
0.57
0.43
0.5
0.43
100

hsa-miR-328
hsa-miR-409-3p
hsa-miR-200a
hsa-miR-23a
hsa-miR-199a-3p
hsa-miR-214-5p
hsa-miR-221
hsa-miR-210
hsa-miR-365
hsa-miR-99a
hsa-miR-27b
hsa-miR-149
hsa-miR-23b
hsa-miR-152
hsa-miR-127
hsa-let-7c
hsa-miR-100
hsa-miR-146a
hsa-miR-214
hsa-miR-193b
hsa-miR-196b
hsa-miR-218
hsa-miR-139-5p
hsa-miR-489
hsa-miR-574-3p

0.54
0.54
0.53
0.46
0.55
0.41
0.57
0.49
0.57
0.45
0.53
0.39
0.53
0.52
0.48
0.56
0.59
0.58
0.3
0.55
0.51
0.41
0.59
0.24
0.44

Appendix 2
Detected miRNA in human skin at 1 hour following UV-exposure (log 2 fold change)
miRNA
hsa-mir-145-5p
hsa-mir-668-3p
hsa-mir-133a-3p
hsa-mir-23a-5p
hsa-mir-143-5p

log 2 fold change at 1 hour post-SSL
-0.54689
0.594605
-0.61168
-0.54239
-0.57547
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Appendix 3
Detected miRNA in three subtypes of cuSCC (log 2 fold change)
miRNA
hsa-mir-6510-3p
hsa-mir-4532
hsa-mir-6089
hsa-mir-486-5p
hsa-mir-3621
hsa-mir-204-5p
hsa-mir-184
hsa-mir-218-1-3p
hsa-mir-6511a-3p
hsa-mir-3656
hsa-mir-3178
hsa-mir-3195
hsa-mir-214-3p
hsa-mir-3663-3p
hsa-mir-145-5p
hsa-mir-211-5p
hsa-mir-1247-5p
hsa-mir-375
hsa-mir-149-5p
hsa-mir-718
hsa-mir-574-3p
hsa-mir-3665
hsa-mir-3196
hsa-mir-125b-5p
hsa-mir-378a-5p
hsa-mir-6087
hsa-mir-6511b-3p
hsa-mir-652-3p
hsa-mir-139-5p
hsa-mir-4655-3p
hsa-mir-100-5p
hsa-mir-762
hsa-mir-1538

Xeroderma
Immunosuppressed
Pigmentosum cuSCC
cuSCC
-0.12
-1.82
1.29
-1
0.34
-0.8
-1.27
-3.76
0.48
-0.69
-3.08
-3.28
0.17
-0.1
-0.15
-1.15
0.25
-1.34
1.32
-1.45
1.07
-0.83
1.69
-0.61
-1.19
-0.97
0.28
-0.55
-2
-0.3
-4.91
-2.42
-1.68
-1.86
-0.22
-1.57
-0.48
-0.73
0.23
-0.71
-1.39
-0.28
0.86
-1.09
1.05
-0.28
-1.75
-1.32
0.78
-0.84
1.63
-0.59
-0.1
-0.42
2.38
-2.12
-1.21
-1.48
1.12
0.29
-1.16
-1.42
0.28
-0.45
0.47
-0.5
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UV-driven
cuSCC
3.2
2.55
2.48
2.35
2.26
2.26
2.19
2.15
2.1
2.08
2.06
1.98
1.95
1.93
1.79
1.77
1.75
1.72
1.6
1.54
1.53
1.53
1.52
1.5
1.5
1.47
1.47
1.46
1.46
1.45
1.43
1.39
1.37

hsa-mir-486-3p
hsa-mir-197-3p
hsa-mir-4508
hsa-mir-193a-5p
hsa-mir-5787
hsa-mir-296-5p
hsa-mir-664b-3p
hsa-mir-4497
hsa-mir-125a-5p
hsa-mir-4634
hsa-mir-4739
hsa-mir-2110
hsa-mir-664a-3p
hsa-mir-338-5p
hsa-mir-451a
hsa-mir-509-3p
hsa-mir-497-5p
hsa-mir-1247-3p
hsa-let-7d-3p
hsa-mir-3605-3p
hsa-mir-30a-3p
hsa-mir-4707-5p
hsa-mir-532-3p
hsa-mir-485-5p
hsa-mir-99a-3p
hsa-mir-508-3p
hsa-mir-574-5p
hsa-mir-766-3p
hsa-mir-320b
hsa-mir-99a-5p
hsa-mir-320a
hsa-mir-125b-1-3p
hsa-mir-4516
hsa-mir-195-5p
hsa-mir-146b-3p
hsa-mir-664a-5p
hsa-mir-3609
hsa-let-7e-3p
hsa-mir-365a-5p

-0.21
-0.1
1.83
0.35
0.72
1
0.01
1.32
-1.24
-0.9
1.52
0.43
-0.48
-0.41
0.53
-0.78
-0.5
0.02
1.61
0.81
0.44
1.13
1.07
0
0
-1.06
2.17
0.75
-0.48
-1.97
-0.38
0.84
3.27
-2.57
0.88
-0.64
0.07
0.88
0.72
103

-2.77
-0.35
-1.06
-1.32
-0.28
-0.22
-0.86
-0.34
-0.61
-0.09
-0.43
-0.86
-0.89
-1.39
-2.97
-1.94
-0.24
-1.62
-0.53
-0.78
-1.09
-0.5
-0.59
-0.74
-0.66
-1.53
0.01
-0.04
-0.7
-1.1
-0.68
-0.88
-0.05
-0.59
-1.02
-0.87
0.2
0.09
0.25

1.34
1.33
1.27
1.26
1.25
1.22
1.22
1.21
1.16
1.16
1.11
1.1
1.1
1.09
1.07
1.04
1.02
1.01
0.99
0.97
0.97
0.93
0.93
0.93
0.93
0.92
0.89
0.89
0.87
0.86
0.86
0.84
0.82
0.81
0.8
0.78
0.78
0.77
0.73

hsa-mir-30c-2-3p
hsa-mir-193b-3p
hsa-mir-144-3p
hsa-mir-1275
hsa-mir-1915-3p
hsa-mir-214-5p
hsa-mir-4492
hsa-mir-432-5p
hsa-mir-514a-3p
hsa-mir-199a-5p
hsa-mir-140-3p
hsa-mir-378a-3p
hsa-mir-30d-5p
hsa-mir-365a-3p
hsa-mir-365b-3p
hsa-mir-99b-5p
hsa-mir-330-3p
hsa-mir-6126
hsa-mir-324-3p
hsa-mir-127-3p
hsa-mir-566
hsa-mir-30a-5p
hsa-mir-331-3p
hsa-mir-129-2-3p
hsa-mir-3158-3p
hsa-mir-26a-5p
hsa-mir-4488
hsa-mir-3651
hsa-mir-191-5p
hsa-mir-324-5p
hsa-mir-335-5p
hsa-mir-125a-3p
hsa-mir-150-5p
hsa-mir-767-3p
hsa-mir-320c
hsa-mir-20b-5p
hsa-mir-185-3p
hsa-mir-26b-3p
hsa-mir-24-1-5p

0.33
0.52
3.54
1.72
1.77
1.67
2.91
0.06
0.26
-0.01
-0.53
-0.5
-0.9
1.7
1.7
-0.46
0.89
2.24
2.12
-1.43
1.46
-1.49
1.92
-0.87
1.76
-1.35
3.98
0.53
-0.62
2.58
0.72
1.48
-1.95
1.14
0.91
0.18
1.26
1.82
1.58
104

-1.1
0.58
-2.09
-0.27
0.05
-0.03
-0.95
-0.81
-1.16
-0.36
-0.84
-0.72
-0.77
-0.12
-0.12
-0.15
-0.63
-0.03
0.25
-0.46
-0.03
-1.05
0.47
0
-0.77
-0.44
0.25
1.06
-0.56
-0.21
-0.83
0.01
-1.08
1.55
0.1
-2.12
0.01
-0.11
0.83

0.7
0.69
0.67
0.67
0.66
0.66
0.63
0.63
0.6
0.53
0.49
0.49
0.49
0.47
0.47
0.47
0.46
0.35
0.31
0.3
0.28
0.27
0.25
0.24
0.21
0.21
0.2
0.2
0.2
0.16
0.15
0.14
0.13
0.11
0.1
0.1
0.09
0.09
0.08

hsa-mir-15b-5p
hsa-mir-941
hsa-mir-30c-5p
hsa-mir-150-3p
hsa-mir-93-3p
hsa-mir-3200-3p
hsa-mir-339-5p
hsa-mir-10b-5p
hsa-mir-505-3p
hsa-mir-106a-5p
hsa-mir-30b-5p
hsa-mir-129-5p
hsa-mir-425-3p
hsa-mir-363-3p
hsa-mir-4326
hsa-mir-106b-3p
hsa-let-7d-5p
hsa-mir-99b-3p
hsa-mir-146a-5p
hsa-let-7g-3p
hsa-mir-33a-3p
hsa-mir-484
hsa-mir-4746-5p
hsa-mir-409-3p
hsa-mir-550a-3p
hsa-mir-3129-3p
hsa-mir-744-3p
hsa-mir-221-5p
hsa-let-7g-5p
hsa-mir-641
hsa-mir-221-3p
hsa-mir-455-3p
hsa-mir-345-5p
hsa-mir-576-5p
hsa-mir-185-5p
hsa-mir-769-5p
hsa-mir-3117-3p
hsa-mir-6499-5p
hsa-mir-148b-3p

1.5
2.07
-0.62
-0.26
1.73
0.23
2.37
-1.7
2.17
0.43
-0.18
-0.28
1.58
1.15
1.16
1.21
0.42
1.86
-0.58
1.34
1.76
0.99
1.05
-1.1
1.81
0.56
0.73
2.06
0.89
1.19
1
1.77
1.85
2.02
1.97
-0.39
0.9
0.94
2.26
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-0.08
-0.36
-0.37
-0.62
0.61
-0.65
0.64
-0.59
0.01
-1.18
-0.44
0.03
-0.26
-2.12
0.27
-0.26
-0.36
0.35
-0.96
0.54
0.99
-0.23
0.48
-0.23
-0.1
1.05
0.91
0.28
-0.38
0.28
0.46
0.43
-0.15
0.33
-1.04
-0.41
0.99
0.74
0.26

0.06
0.05
0.03
0.03
0
0
0.02
0.06
0.08
0.08
0.09
0.1
0.11
0.11
0.15
0.16
0.16
0.18
0.19
0.2
0.2
0.21
0.22
0.22
0.25
0.26
0.26
0.26
0.27
0.27
0.28
0.29
0.31
0.33
0.34
0.36
0.37
0.37
0.38

hsa-mir-369-3p
hsa-mir-200b-3p
hsa-mir-654-5p
hsa-mir-425-5p
hsa-mir-2277-5p
hsa-mir-4478
hsa-mir-4784
hsa-mir-126-3p
hsa-mir-23a-3p
hsa-mir-532-5p
hsa-mir-4446-3p
hsa-mir-1185-1-3p
hsa-mir-132-3p
hsa-mir-548av-3p
hsa-mir-98-5p
hsa-mir-708-5p
hsa-mir-24-3p
hsa-mir-548o-3p
hsa-mir-142-3p
hsa-mir-6724-5p
hsa-mir-1307-3p
hsa-mir-5701
hsa-mir-1293
hsa-mir-708-3p
hsa-let-7f-5p
hsa-mir-182-5p
hsa-mir-25-3p
hsa-mir-4443
hsa-mir-103a-3p
hsa-mir-27b-3p
hsa-mir-614
hsa-mir-490-3p
hsa-mir-454-3p
hsa-mir-27a-5p
hsa-mir-107
hsa-mir-28-5p
hsa-mir-7-1-3p
hsa-mir-205-3p
hsa-mir-20a-5p

1.87
0.56
-0.73
0.33
1.01
4.13
1.49
-1.51
-0.22
1.46
0.24
0.7
1.47
1.73
1.77
1.67
0.04
1.74
1.79
3.16
2.73
3.24
0.66
3.6
0.68
0.63
0.63
2.91
0.09
0.78
4.07
2.3
2.04
2.56
0.73
-0.1
1.73
2.12
0.94
106

0.91
0.62
-0.14
-0.72
0.38
0.19
1.1
-0.29
0.59
-0.06
0.01
0.12
-0.22
0.35
0.03
0.65
0.31
0.38
0.12
0.41
0.18
0.56
0.4
0.63
0.02
-0.18
-0.06
0.29
-0.11
0.46
1.42
1.82
0.26
0.35
-0.62
0.08
0.67
1.53
0.23

0.4
0.41
0.42
0.42
0.43
0.44
0.44
0.44
0.45
0.47
0.49
0.51
0.51
0.51
0.51
0.51
0.52
0.52
0.52
0.54
0.55
0.55
0.56
0.58
0.59
0.59
0.6
0.61
0.61
0.61
0.62
0.63
0.64
0.65
0.65
0.66
0.67
0.68
0.68

hsa-mir-1268a
hsa-mir-212-3p
hsa-mir-93-5p
hsa-mir-330-5p
hsa-mir-181c-5p
hsa-mir-2355-5p
hsa-mir-4730
hsa-mir-181b-5p
hsa-mir-151a-3p
hsa-mir-3180
hsa-mir-3180-3p
hsa-mir-1307-5p
hsa-mir-200c-5p
hsa-mir-340-3p
hsa-mir-660-5p
hsa-mir-450b-5p
hsa-mir-25-5p
hsa-mir-665
hsa-mir-17-5p
hsa-mir-16-5p
hsa-let-7i-5p
hsa-mir-1246
hsa-mir-7-5p
hsa-mir-582-5p
hsa-mir-222-5p
hsa-mir-146b-5p
hsa-mir-132-5p
hsa-mir-18a-5p
hsa-mir-148b-5p
hsa-mir-615-3p
hsa-mir-493-5p
hsa-mir-130b-5p
hsa-mir-17-3p
hsa-mir-493-3p
hsa-mir-3182
hsa-mir-454-5p
hsa-mir-181c-3p
hsa-mir-224-5p
hsa-mir-1303

1.99
2.68
0.54
2.66
0.75
2.72
3.36
0.61
0.17
0.19
0.19
4.07
1.4
2.01
1.07
3.46
0.81
1.06
0.71
-0.27
1.04
1.4
1.79
2.99
1.01
-0.26
1.76
2.95
2.75
2.48
1.21
2.5
2.61
0.21
1.17
1.78
2.02
0.5
1.58
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0.77
0.08
-0.3
0.84
0.06
1.39
0.66
0.5
0.24
0.84
0.84
1.8
1.25
0.25
0.18
2.03
0.73
1.01
0.17
-0.5
0.4
1.46
1.98
0.61
-0.25
-0.53
0.02
0.96
0.78
1.38
0.7
0.68
0.05
0.67
1.35
0.69
0.58
0.94
0.67

0.7
0.71
0.72
0.74
0.74
0.75
0.76
0.76
0.77
0.77
0.77
0.78
0.8
0.8
0.82
0.83
0.84
0.85
0.86
0.86
0.87
0.87
0.88
0.88
0.88
0.89
0.9
0.91
0.91
0.92
0.92
0.93
0.93
0.93
0.95
0.95
0.96
0.96
0.96

hsa-mir-22-3p
hsa-mir-4448
hsa-mir-629-5p
hsa-mir-106b-5p
hsa-mir-223-3p
hsa-mir-196b-5p
hsa-mir-200a-5p
hsa-mir-331-5p
hsa-mir-1285-3p
hsa-mir-34c-5p
hsa-mir-944
hsa-mir-27a-3p
hsa-mir-193a-3p
hsa-mir-187-3p
hsa-mir-323b-3p
hsa-mir-431-5p
hsa-mir-15b-3p
hsa-mir-192-5p
hsa-mir-141-5p
hsa-mir-27b-5p
hsa-mir-15a-5p
hsa-let-7a-3p
hsa-mir-455-5p
hsa-mir-16-2-3p
hsa-mir-135b-5p
hsa-mir-421
hsa-mir-452-5p
hsa-mir-450a-5p
hsa-mir-155-5p
hsa-mir-24-2-5p
hsa-mir-1269a
hsa-mir-130b-3p
hsa-mir-181a-3p
hsa-mir-196a-5p
hsa-mir-340-5p
hsa-mir-22-5p
hsa-mir-142-5p
hsa-mir-424-5p
hsa-mir-424-3p

0.38
1.08
1.5
1.67
1.17
0.78
3.22
2.18
3.4
1.42
3.78
0.77
2.78
0.78
0.35
1.41
2.09
-0.05
2.09
0.26
1.87
3.84
1.92
2.85
3.14
2.27
2.22
2.75
0.88
2.63
1.56
1.58
1.64
0.43
2.26
2.72
-0.03
3.36
2.4
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0.45
1.47
-0.03
0.26
-0.88
1.29
1.38
0.7
1.13
1.17
1.63
1.4
0.92
0.81
0.26
0.65
1.46
0.02
1.61
0.57
-0.46
1.45
1.18
-0.3
3.41
0.3
0.78
1.71
0.36
0.84
2.96
0.59
0.72
1.55
0.37
1.35
-0.56
1.95
1.37

0.98
1.03
1.04
1.05
1.06
1.06
1.07
1.08
1.09
1.1
1.14
1.16
1.17
1.17
1.22
1.22
1.23
1.27
1.29
1.29
1.31
1.34
1.37
1.38
1.41
1.42
1.42
1.44
1.46
1.52
1.62
1.63
1.64
1.65
1.68
1.73
1.77
1.82
1.88

hsa-mir-21-5p
hsa-mir-31-3p
hsa-mir-21-3p
hsa-mir-31-5p

2.08
4.16
5.2
2.64

2.1
3.96
2.56
3.47

2.61
2.73
3.01
3.28

Appendix 4
Potential miR-21 targets expression in SCCT8 treated with miR-21 inhibitor and mimic (log 2
fold change)
Proteins
miR-21 inhibitor
miR-21 mimic
ABI2
0.345161903
-0.265190391
ANP32E
0.553348599
-0.100458185
ANXA1
0.272606179
-0.432385806
AP1S2
0.336497486
-0.295161943
BID
0.55506518
-0.251256637
CAMSAP1
0.227075164
-0.203996023
CDS1
0.258788099
-0.162024316
CEP44
0.1440208
-0.247960871
CHM
0.555661009
-0.252766245
DAZAP2
0.356531027
-0.49251089
DCTN3
0.325878418
-0.114100454
FBXL2
0.25015208
-0.186006504
FGFR1OP2
0.153577475
-0.114399888
GINS1
0.186697023
-0.229961254
GNPDA2
0.612320893
-0.165388235
GSS
0.220859049
-0.124222386
GTPBP1
0.25680205
-0.292331839
GYG1
0.48055174
-0.147299543
IPO11
0.56435111
-0.314422377
MAPKAP1
0.122066129
-0.114405747
MTMR12
1.091099353
-1.112174201
MYEF2
0.29148543
-0.35450327
MYO1E
0.230829671
-0.112699661
NRIP1
0.1018217
-0.136875696
NSUN2
0.334317205
-0.135366843
PAN3
0.542806496
-0.118429218
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POLD3
PPP1R15B
PPP1R9A
PTPRE
RAP2A
SC5D
SNIP1
SUB1
TIMP2
TMEM192
TMEM206
TMEM63A
TP53BP2
TRAPPC8
WDR7

0.354945229
0.457459773
0.247218979
0.362242838
0.250560209
0.339750765
0.145610548
0.171701999
0.411778561
0.270363104
0.662488242
0.12315484
0.352457927
0.700310521
0.155220126

-0.271091152
-0.572173417
-0.479860937
-0.107814551
-0.214061809
-0.10653511
-0.101109749
-0.183746082
-0.295892187
-0.127320992
-0.183709032
-0.126504127
-0.131351061
-1.18224429
-0.149321955

Appendix 5
Potential miR-21 tar3gets expression in SCCT8 treated with miR-31 inhibitor and mimic (log 2
fold change)

Protein
miR-31 inhibitor
miR-31 mimic
ABI2
0.271379139
-0.184046531
AHNAK2
0.167461929
-0.325298252
BAIAP2
0.110979987
-0.196978204
CNTN5
0.139161691
-0.219358741
CPNE8
0.110637696
-0.334887547
DENND1A
0.322071289
-0.192198154
EXOC7
0.104500081
-0.190625069
EXOC8
0.100481103
-0.11109884
FAM204A
0.156586526
-0.43724134
FAM210B
0.105067802
-0.138816402
FAM219A
0.278536732
-0.290551671
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FOSL2
GSE1
HECTD3
IER3IP1
JDP2
LPP
LUC7L
MANEAL
MTM1
NELFB
PGM2L1
PLEKHA1
RAB38
SEZ6L2
SH3BGRL
SHB
SLC7A2
SMAD3
SNRNP27
SPAST
SSH1
SUCO
TOR2A
UBE2B
ZBTB10
ZNF354C

0.129112392
0.507165474
0.189476314
0.11347451
1.032866941
0.269905846
0.114884396
0.286967471
0.130448108
0.105361157
0.565088447
0.24193254
0.233814069
0.155522765
0.125236086
0.21462463
0.12151903
0.152220698
0.39888721
0.122677515
0.984903464
0.180281183
0.261281157
0.145870993
0.172208086
0.17538168

-0.117357719
-0.656015902
-0.449661897
-0.305169834
-0.869091184
-0.121342165
-0.103246439
-0.192899519
-0.163511833
-0.155317708
-0.167089403
-0.187203634
-0.222847641
-0.226193472
-0.187369158
-0.1498071
-0.333630398
-0.697041946
-0.172124386
-0.127890117
-0.116403429
-0.199824379
-0.123233029
-0.169010865
-1.255087134
-0.295982853

Appendix 6
Potential targets of miR-181a

1
2
3
4
5
6

miR-181a predicted target genes
AFTPH
ANKRD13C
ARF6
ATP8A1
BAPX1
BCL2
111

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

BTBD3
CCDC6
CCNG1
CDX2
DDIT4
FAM160A2
FBX011
FBX028
FBX033
GATA6
GIGYF1
GPR1237B
KRAS
KIAA
KLADCS
LBR
LCLAT1
METAP1
MTMR12
NFYB
NLK
NOCH2
NOL4
NR6A1
NRP1
NUPL1
PDX3X
PITPNB
PLAG1
PLCL2
PLXDC2
PROX1
PUM1
RLF
RNF34
SCD
SFRS7
SLC37A3
SLC7A11
112

46
47
48
49
50
51
52
53
54

STCH
TGFBR3
TIAL1
TM9SF3
TMED4
TMEM64
YOD1
ZNF148
ZNF445
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